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ABSTRACT 
Colorectal cancer (CRC) is the third most common form of cancer in Sweden. The etiology of CRC is 
considered to be influenced by environmental risk factors on a background of constitutional and acquired 
genetic variations. It is estimated that inherited susceptibility accounts for approximately 35% of all CRC 
cases. The well-known high-risk syndromes familial adenomatous polyposis and Lynch syndrome, 
however, explain less than 5%. The remaining part of the “genetic” group is contributed by risk factors of 
much smaller magnitude, such as mutations in several low-risk alleles. Genome-wide association studies 
have identified multiple genetic loci and single nucleotide polymorphisms (SNPs) associated with an 
increased or decreased risk of CRC. Also, the histopathological profile of CRC shows considerable 
variation in relation to sex, age, tumor location, family history and mode of presentation, which could 
speak for different mechanisms of tumor development in different groups of patients.   
The aim of paper I was to determine whether 11 newly identified genetic susceptibility loci were 
associated with tumor morphology, to confirm them as distinct and etiologically different risk factors in 
colorectal carcinogenesis. To that end, we analyzed 15 histological features in 1572 cases of 
consecutively operated CRCs during the years 2004-2006. Of the tested loci, five SNPs were 
significantly associated with morphological parameters such as poor differentiation, mucin production 
and decreased frequency of Crohn-like peritumoral reaction and desmoplastic response (p=0.004). The 
results are consistent with pathogenic variants in several loci acting in distinct CRC morphogenic 
pathways.  
The aim of paper II was to provide a systematic histopathological characterization of CRC in the patient 
material above by comparing the morphology of tumors in men and women, in different age groups, in 
different anatomical locations, and in sporadic and familial cases, in order to isolate the effects of these 
four factors. Women had significantly more tumors with a high level of tumor infiltrating lymphocytes 
compared to men (p=0.002). Patients aged <60 years had less often multiple tumors but more often 
perineural invasion, infiltrative tumor margin (p<0.0001) and high AJCC-, T- and N-stage tumors 
(p<0.0001 for AJCC stage III) compared to patients >75 years. The results indicate that younger patients 
have a more aggressive disease. Most histological features showed a significant difference between left 
colon and rectum compared to right colon. Tumors in left colon and rectum were smaller and showed  
less often poor-, mucinous- or medullary differentiation or a circumscribed tumor margin (p<0.0001 for 
most features). Also, they were generally of a lower AJCC- and T-stage compared to right-sided lesions. 
The majority of features showed a gradient from right colon to rectum. The findings are in line with 
tumors in different locations having different genetic and embryological backgrounds as well as 
developing in different physiological settings. The only difference between the sporadic and familiar 
group was seen in vascular invasion which was more common among the familial cases (p=0.012). 
The aim of paper III was to compare the clinicopathological profile of emergency and elective cases of 
CRC in relation to sex, age groups, location, and family history of CRC. In a multivariate analysis of 976 
tumors from Stockholm County emergency cases more often showed multiple tumors, signet-ring cells, 
desmoplasia, vascular and perineural invasion, infiltrative tumor margin and high AJCC-, T- and N-stage 
tumors (p<0.0001 for several features). The findings could speak for emergency CRCs being an 
inherently different group of tumors with a more aggressive biology. 
The aim of paper IV was to use the family history of cancer in 1720 patients with CRC together with 
genotyping and tumor morphology in order to find support for and define new CRC syndromes. There 
were significantly more cancers (other than CRCs) in the family history of the familial CRC cases 
compared to the sporadic CRC cases (p<0.001). There were also more bladder, prostate and gastric 
cancers as well as melanomas. One SNP, previously associated with both CRC and prostate cancer, was 
confirmed to be more common in families with CRC + prostate cancer. There were some support for 
different morphological profiles in four of the five tested syndromes with p=0.010 for an association 
between CRC + gastric cancer and Crohn-like peritumoral reaction. 
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1. INTRODUCTION TO COLORECTAL CANCER 
 
Epidemiology 
Colorectal carcinoma (CRC) represents almost 10% of all new cancers worldwide and 
ranks as the fourth most common cancer in men and third in women. The age 
standardized incidence varies at least 25-fold with high rates in industrialized,  
high-resource countries of Europe, Australia, New Zealand, North America and Japan 
(40-60/100 000) and much lower rates in other countries in Asia and Africa 
1, 2
.  
Among immigrants and their descendants incidence rates rapidly increase up to those of 
their adopted countries, indicating that lifestyle, diet and environment are important risk 
factors 
1
. Rates of rectal cancer are about 50% higher and rates of colon cancer about 20% 
higher in men than in women 
3
. CRC is rare before the age of 40 years except in 
individuals with a predisposing condition. The incidence rate increases with age up to a 
peak in the seventh decade (mean age 60-65 years). The worldwide mortality rate is about 
half the incidence rate (608 000 deaths in 2002) and CRC is the fourth leading cause of 
death in cancer worldwide 
4
. While the prevalence of CRC has increased over the last 
century, mortality rates have declined as a result of improved treatment, screening and 
surveillance 
5
. 
In Sweden CRC is the third most common form of cancer in both men and women.  
It contributes to about 7% of all cancer diagnoses with approximately 5000 new cases per 
year and the lifetime risk of developing CRC in Sweden is 5-7% 
6
. The relative 5-year 
survival for colon cancer diagnosed 1993-1995 in Sweden was 57% for men and 59% for 
women. The corresponding figures for rectal cancer were 54% and 60% respectively 
6
.  
 
The prognosis of CRC is strongly correlated to tumor stage which is based on the depth of 
tumor infiltration through the bowel wall and the presence of lymph node or distant 
metastases. The 5-year survival is >90% in stage I, 75-85 in stage II, 45-60% in stage III 
and 0-5% in stage IV 
7
.  
Etiology 
The etiology of CRC is today considered to be influenced by environmental risk factors 
on a background of constitutional and acquired genetic variations. Based on studies of 
twins it is estimated that 35% of CRCs have a potentially identifiable genetic cause 
8
. 
Among these are the well-known syndromes familial adenomatous polyposis (FAP) and 
Lynch syndrome (LS). These two conditions however explain less than 5% of all CRCs. 
The remaining part of the “genetic” group is contributed by risk factors of much smaller 
magnitude, such as mutations in several low-risk alleles, as has been shown in studies of 
CRC as a complex disease 
9
. The genetics of CRC and the importance of family history 
for this disease will be dealt with in Chapter 2 and 3. Most CRCs are sporadic and occur 
in individuals over 50 years of age. These tumors develop as the consequence of 
 4 
environmental carcinogenic exposure and secondary genetic or epigenetic events in 
somatic cells 
10
. 
Traditionally, several risk factors associated with an affluent western lifestyle have been 
implicated in the etiology of CRC. These include a diet rich in calories and animal fat, a 
high consumption of red meat and processed foods as well as a lack of fresh fruit, 
vegetables and dietary fibre. Obesity, alcohol and smoking are also risk factors for CRC, 
while physical activity, dietary calcium supplementation, vitamin D, non-steroidal anti-
inflammatory drugs and estrogen replacement therapy in women exerts a protective 
effect. The inflammatory bowel diseases (IBD) ulcerative colitis and Crohn’s disease 
confer an increased risk of CRC, although there are varying reports regarding the 
cumulative risk. 
Red meat and processed foods 
Observational and prospective studies have shown an association between consumption 
of red meat and an increased risk of CRC 
11, 12
, although there is some inconsistency in the 
reports. Red meat, as well as processed meat, increases fecal levels of N-nitroso 
compounds, which are potentially carcinogenic. Some N-nitroso compounds have 
alkylating agent properties and have been demonstrated to induce changes in the KRAS 
gene which is activated in the oncogenic pathway to CRC 
13
. Red meat also increases the 
level of DNA adducts in the epithelial cells of colon. These adducts are highly reactive 
agents that have been recognized as playing a central role in carcinogenesis 
14
. 
 
Fruits, vegetables and fibre 
Diets low in fruits and vegetables have been associated with an increased risk of CRC in 
observational studies 
15, 16
. A high intake of fibre has been correlated to a reduced risk of 
CRC in some studies 
17, 18
, but not in others 
19, 20
. In a systematic review of five studies it 
was concluded that there was insufficient evidence to state that increased dietary fibre 
reduced the incidence or recurrence of adenomatous polyps which are precursor lesions to 
CRC 
21
. Proposed mechanisms for dietary fibre to reduce the development of CRC are 
decreased exposure of the colonic mucosa to carcinogens (by shortening the intestinal 
transit time) and the fermentation of fibre by colonic bacteria to produce short-chain fatty 
acids such as butyrate, which has been demonstrated to induce cell cycle arrest, 
differentiation and/or apoptosis in vitro
 22
.  
 
Obesity 
An elevated body mass index has been linked to the development of both colonic 
adenomas and CRC 
23, 24
. Obesity is associated with the metabolic syndrome, behind 
which either the presence of insulin resistance or visceral adiposity is the driving force. In 
vitro studies have shown that insulin promotes cellular proliferation, inhibits apoptosis in 
colon cancer cell lines and promotes the growth of colorectal cancer in animal models 
25
. 
Hyperinsulinaemia is associated with elevated levels of insulin-like growth factor 1 (IGF-
1) which has been demonstrated to promote cell migration, cell proliferation and 
angiogenesis and inhibit apoptosis and cellular adhesion. Obesity also leads to a change in 
serum levels of adipocytokines such as leptin and adiponectin which in vitro have effect 
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on cell proliferation, angiogenesis and promotion of tumorigenesis and could therefore 
contribute to the development of CRC 
26
. Visceral adiposity has been linked to a state of 
chronic low-grade inflammation and persistent activation of the nuclear transcription 
factor NK-κB with subsequent transcription of genes promoting tumorigenesis 27. 
 
Physical activity 
A number of potential mechanisms for physical activity to reduce the risk of CRC have 
been suggested, including decreased gastrointestinal transit time, altered immune function 
and the role of insulin and IGF-1 according to above 
28
. High levels of insulin and IGF-1 
are associated with low exercise levels.  Interestingly, mutations in both KRAS and TP53, 
genes involved in the CRC pathway, have been linked to reduced levels of physical 
activity 
29, 30
. 
 
Smoking and alcohol 
There is currently insufficient evidence to establish a causal relationship between smoking 
and CRC, but prospective studies have shown an increased risk ratio among smokers for 
both colon and rectal cancer 
31, 32
. It has been reported that smoking may be associated 
with particular subtypes of tumors, such as cancers showing p53 overexpression or 
transversion mutations in the KRAS gene 
33
.  
 
Pooled data from cohort studies have showed an increased risk ratio of developing CRC 
in those drinking >45g alcohol/day 
34
. It has been proposed that a decreased intake of 
folate, which participates in DNA synthesis, among patients with significant alcohol 
dependency could explain the higher risk of CRC in this group 
35
.  
 
Ulcerative colitis 
Ulcerative colitis (UC) is an inflammatory bowel disease of unknown etiology affecting 
children and adults with a peak incidence in the early third decade. CRC is a serious 
complication and accounts for 10-15% of all deaths in IBD patients. In different studies 
the cumulative risk for CRC after 20 years of UC varies from 1 to 34%. This wide range 
is probably explained by variation in age at diagnosis, gender, extent and duration of the 
disease as well as use of different patient populations. In a meta-analysis the risk of CRC 
was 2% after 10 years, 8% after 20 years and 18% after 30 years of disease 
36
. The risk is 
highest for colitis involving the whole colon, while ulcerative proctitis is not associated 
with an increased risk. UC-associated cancers are often multiple and evolve from flat 
lesions through low-grade and high-grade dysplasia, or from raised dysplastic lesions 
(dysplasia-associated lesion or mass, DALM). The molecular alterations in UC-associated 
CRCs are similar to sporadic CRCs, but seem to differ in frequency and sequence. In 
contrast to sporadic carcinomas, APC and KRAS mutations occur late in the carcinogenic 
process, while changes in TP53 occur early. 15% of UC-related carcinomas show a high 
level of microsatellite instability. In addition, oxidative stress, cyclooxygenas-2 (COX2), 
cytokines such as TNFα and IL-10, growth factors and gastrointestinal microbiota are 
thought to play a key role in the carcinogenesis of CRC in patients with UC 
3, 37
. 
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Gene-diet interactions 
In brief, the molecular pathways that underlie the epidemiological associations are poorly 
understood because of complex interactions that may involve dietary patterns, nutrient 
composition of foodstuffs, food preparation techniques, hormonal effects, genetic 
characteristics and gene-diet interactions. In a meta-analysis to detect potential 
interactions between ten single nucleotide polymorphisms (SNPs) associated to CRC and 
selected risk factors including sex, body mass index, smoking, alcohol, dietary intake of 
red meat, vegetables, fruit and fibre, the only gene-environment interaction that was 
statistically significant was between one SNP and vegetable consumption 
38
. 
Symptoms and signs 
In its early stages CRC is usually asymptomatic. There is no good correlation between the 
duration of symptoms and tumor stage. The main symptoms are change in bowel habits, 
especially obstipation (sometimes alternating with diarrhea), and haematochezia.  
Associated abdominal distension and pain may follow. Right-sided tumors may produce 
less obstructive symptoms but present themselves with anemia, weight loss and impaired 
general condition. Left-sided tumors however tend to cause obstructive symptoms, change 
in bowel habits, haematochezia or mucus in stools. Rectosigmoid lesions can produce 
tenesmus and rectal bleeding. Impaired general status, vomiting, cachexia, ascites and 
anemia are signs of advanced disease 
39
. 15-30% of CRCs present themselves as surgical 
emergencies, most often as obstruction with colon ileus or perforation 
40, 41
.  
Diagnostics 
The primary work-up of patients with suspected CRC includes medical history, family 
history, physical examination and colonoscopy. If the colonoscopy reveals a tumor,  
a computerized tomography of the abdomen and thorax should be performed in order  
to visualize any spread of the tumor. All patients with suspected or confirmed CRC 
should be referred to a surgical clinic where further investigation can be performed if 
necessary 
39
. 
Colonoscopy 
Regardless of whether a rectal tumor is found or not, a colonoscopy ought to be 
performed to exclude any synchronous tumor. Colonoscopy has an advantage over 
barium-enema and computed tomographic colonoscopy (“virtual colonoscopy”) since  
it allows for biopsies to be taken (Figure 1A). In addition, the therapeutic removal of 
small lesions such as polyps by snare polypectomy or endoscopic mucosal resection is 
possible 
39
.  
 
Transrectal ultrasonography 
This method has traditionally been used to stage rectal cancer preoperatively since it 
allows an estimation of the depth of tumor invasion in the wall, especially among 
superficial tumors 
42
. Regional lymph nodes may also be visualized, although transrectal 
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Figure 1. A. Picture from a colonoscopy showing an elevated plaque-like cancer. Biopsy forceps 
visible in the lower part. B. MRI of a rectal cancer. T and arrow indicates tumor. 
           
                            
 
ultrasonography cannot reliably separate metastatic lymph nodes from benign ones 
43
. 
Due to this and the technical evolution of magnetic resonance imaging (see below) the 
latter method has largely replaced transrectal ultrasonography in the preoperative staging 
of rectal cancer. 
 
Magnetic resonance imaging (MRI) 
High-resolution MRI has been shown to be superior to both computerized tomography 
and transrectal ultrasonography for local staging of rectal cancer 
44 
(Figure 1B). It has the 
ability to differentiate tumor from the lamina muscularis propria and can delineate the 
mesorectal fascia (MRF) which forms the circumferential resection margin (CRM) at 
operation 
45
. The presence of regional lymph node metastases can be assessed although 
the method still has its limitations 
39
. 
 
Abdominal ultrasound (US) 
This is the most common imaging method used to evaluate the liver for metastases. 
Preoperative examination shows synchronous liver metastases in 10-15% of CRC cases. 
Enhancement with contrast improves both sensitivity and specificity 
39
. 
 
Computerized tomography (CT) and other methods 
CT is an alternative to US in the search for liver metastases. With contrast enhancement 
this imaging modality has a higher diagnostic accuracy than US without intravenous 
contrast. CT is also an efficient method to detect metastases and recurrence after  
surgery 
39
 and is used preoperatively to screen for pulmonary metastases. Pulmonary  
X-ray is sometimes done preoperatively. Positron emission tomography (PET) and 
skeletal scintigraphy are used in selected cases to detect widespread disease. 
Surgical treatment 
Curative resection is the single most important factor for patient survival. Surgery is the 
primary treatment for CRC and can be done as either an open or laparoscopic procedure. 
A B 
 8 
The latter is less common in Sweden where about 5% of rectal cancer operations are done 
with laparoscopy. Careful preoperative assessment of the extent of tumor spread, 
involvement of the MRF and TNM-staging is important. This is preferably done at 
multidisciplinary team (MDT) conferences where surgeons, radiologists, oncologists and 
pathologists discuss the need of preoperative radio- or chemotherapy, possible inclusion 
in any study and the type of surgery.  Even if curative surgery is impossible due to 
metastatic disease it might be worthwhile to try to remove the primary tumor to relieve 
the patient from obstructive symptoms or bleeding. An alternative is to offer the patient 
chemotherapy and to evaluate the result after two to three months. If the response is good 
curative surgery might then be considered 
39
. 
The aim of CRC surgery is to remove the tumor-bearing segment of the bowel with 
sufficient surgical margins as well as the mesentery and regional lymph nodes of that 
segment. Adequate removal of lymph nodes is important not only for postoperative TNM-
staging but may also have therapeutic importance. Growth by the tumor onto adjacent 
organs can be difficult to distinguish macroscopically from fibrous or inflammatory 
adhesions. Even if there is local tumor involvement of the uterus, ovaries or loops of 
small bowel there might not be distant metastases why an en-bloc resection might still be 
curative. As in all curative oncologic surgery the aim is a free longitudinal margin of at 
least 10 cm. In rectal cancers operated with total mesorectal excision a much narrower 
distal margin is accepted because of the anatomical situation and the distance to the 
external sphincter (see below). For a well-differentiated tumor in rectum a longitudinal 
margin of 1 cm is considered sufficient, but a wider margin is desirable for poorly 
differentiated tumors. If a tumor is found to be fixed and not resectable at exploration one 
should refrain from attempts to remove it. Instead, after creating a loop stoma as a 
diversion, the patient should be referred to an MDT conference where a decision of neo-
adjuvant treatment might be made 
39
. Regardless of the type of tumor preoperatively 
suspected, the surgical procedure should be performed in a standardized way according to 
below. 
 
Colon cancer operations 
Right-sided hemicolectomy is performed for tumors located in the cecum, ascending 
colon, hepatic flexure or the right part of the transverse colon. The ileocolic and right 
colic vessels are divided and the right side of colon including the hepatic flexure and 10 
cm of the distal ileum is resected (Figure 2). Recently, a more radical resection of the 
colonic mesentery and the lymphatic drainage in right-sided hemicolectomy has been 
presented and is becoming increasingly common. In this procedure, where the mesentery 
is removed intact (in analogy to total mesorectal excision,) a five year cancer related 
survival of 91% for stage II and 70% for stage III cancers has been reported 
46
. 
Tumors in the transverse colon are usual operated as an extended right-sided or left- 
sided hemicolectomy if the intention is curative. 
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Left-sided hemicolectomy is done for tumors in the left part of the transverse colon, 
hepatic flexure and the descending colon. In this procedure the inferior mesenteric vessels 
are divided proximally and the left colon including the splenic flexure is removed. 
Sigmoidal resection is used for tumors in the sigmoid. However, nowadays left-sided 
hemicolectomy is preferred in most cases. For tumors close to the rectosigmoid junction a 
high anterior resection should be undertaken with a cylindrical resection of the 
mesocolon/mesorectum at least 5 centimeters below the distal margin of the tumor. 
Subtotal or total colectomy might be considered when there are synchronous tumors in 
both left and right colon, if the patient suffers from FAP or LS or has any other type of 
strong risk factor for multiple CRCs. Ileorectal anastomosis is usually performed in these 
cases. 
Emergency colon resections are common. 15-30% of CRC patients present themselves 
as emergency cases, most often due to obstruction (78%), perforation (10%) or bleeding 
(4%) 
40, 41
. If the tumor is located in the right colon the same type of operation as in 
elective cases can usually be performed and a primary anastomosis can be created. The 
choice of operation for left-sided lesions however remains controversial. In these cases 
the bowel proximal to the obstruction is usually circulatory compromised and shows 
diastatic widening or even perforation according to the law of La Place.  Depending on 
the status of the bowel proximal to the obstruction, several different surgical approaches, 
from subtotal colectomy to segmental resection, may be considered. A primary 
anastomosis might be combined with a temporary relieving loop-ileostomy to limit the 
effects of a possible leakage.  In case of perforation, fecal peritonitis, steroid treatment or 
other high-risk factors for operation, the tumor should be resected, a colostomy created 
and the rectal stump usually left blind (i.e. Hartmann’s procedure). If, however, the cecum 
is severely dilated, discolored or perforated a subtotal or total colectomy is advisable, 
even though it will affect the bowel function with frequent stools and possibly impaired 
fecal continence. In severely debilitated patients it might be wise to refrain from a primary 
anastomosis in favor of creating a double-barrel stoma. A method currently under 
Figure 2. Schematic view of a right-sided 
hemicolectomy. The ileocolic and right colic 
vessels are divided with the mesentery.  
Illustration by Hanna Bringman. 
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evaluation is stenting (i.e placing a short hollow plastic or metallic tube in the obstructed 
part of the tumor) during colonoscopy to keep the lumen open. This can be done either as 
a “bridge to surgery” or as a palliative procedure for inoperable patients.  
                       
Figure 3. Emergency surgery for a left-sided colon cancer which has caused obstruction and 
subsequent dilatation of loops of small and large bowel.         
 
Rectal cancer operations 
Curative surgery for rectal cancer can be performed in basicly three ways: 1. Anterior 
resection with anastomosis, 2. Anterior resection without anastomosis (Hartmann’s 
procedure) or 3. Abdominoperineal amputation of rectum. In addition, there are local, 
procedures such as transanal endoscopic microsurgery (TEM) that may be used for radical 
excision of smaller lesions. 
Anterior resection with anastomosis is performed in 50% of patients and is the most 
common surgical procedure for rectal cancer in Sweden 
47
. It is performed for tumors in 
the middle and upper rectum when a distal margin of at least 1 cm can be achieved 
48
. If 
this is not possible an amputation of the rectum should be undertaken instead. In an 
anterior resection the rectosigmoid colon is mobilized, the pelvic floor opened and the 
inferior mesenteric artery ligated and divided. The tumor is removed according to the 
principle of total mesorectal excision (TME) which was introduced in 1982 by Heald. 
This technique involves a sharp dissection of the avascular plane between the mesorectum 
and pelvic structures down to the pelvic floor. The dissection outside the mesorectal 
fascia ensures a complete resection of the mesorectum belonging to the tumor-bearing 
part of the rectum (Figure 4) 
49
. The introduction of TME has dramatically improved local 
tumor radicality with local recurrence rates usually between 3 and 11% today 
50, 51
. After 
the excision, the remaining part of rectum is connected by a side-to-end anastomosis to 
distal colon or to a colonic reservoir. This can be done either hand-sewed or, more 
commonly, by using a circular stapling device. The frequency of clinically observed 
leakage from a low rectal anastomosis is 5 to 10%. Performing a temporary diverting 
loop-ileostomy has been recommended in patients with a low anterior resection to prevent 
pelvic sepsis 
52
. 
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Hartmann’s procedure, which is performed in 10% of rectal cancer patients, is an 
anterior resection without anastomosis. An end-colostomy is created and the rectal stump 
is left blind. This operation is often performed on debilitated patients and patients with 
incontinence or poor preoperative anal sphincter function. 
                             
Figure 4. Specimen from a total mesorectal excision (TME) viewed from the right. The distal 
resection margin is to the right in the picture. Arrows indicate the border between the peritoneal 
reflexion and the mesorectal fascia. 
Abdominoperineal amputation of rectum is a removal of the entire rectum, anal canal 
and anus. It is used in 80% of all patients with a low rectal cancer (i.e. 0.5 cm from the 
anal verge) to ensure an adequate distal resection margin. A permanent terminal sigmoid 
colostomy is created and the resection of the tumor follows the principles of TME all the 
way down to the pelvic floor. Abdominoperineal amputation carries a local recurrence 
rate of 23% 
53
, possibly because of the technical difficulties resulting in perforation of the 
tumor and positive resection margins. Recently the introduction of extralevator 
abdominoperineal resection instead of standard abdominoperineal resection might 
improve the outcome 
54
. 
Screening for colorectal cancer 
CRC fulfills most of the criteria for screening to be applied. The natural history is well 
known compared to many other cancers. CRC may be cured if detected early and even 
prevented by removal of possible precursor lesions such as adenomas. The development 
of CRC is usually slow (5-10 years), making screening for the disease attractive. Possible 
methods for this include sigmoideoscopy, colonoscopy, imaging and molecular stool 
testing. However, the only screening modality that has been subjected to adequate 
scientific assessment is fecal occult blood testing (FOBT). Randomized clinical trials 
have shown a mortality reduction of 15-18% after 10 years follow-up in those targeted for 
screening with Hemoccult test 
55
. In a report from 2005 it was concluded that there is 
sufficient evidence for the effect on mortality of screening for CRC biannually with 
FOBT. There is, however, lack of evidence on the effectiveness of screening as a public 
health service and insufficient knowledge about its harmful effects and costs. Although, 
screening exists in the US and some European countries, in Sweden the recommendation 
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has been to start with feasibility studies and to evaluate the results. Since 2008 a screening 
program for CRC has been implemented in Stockholm County 
55, 56
. 
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2. MOLECULAR GENETICS_________________________    
 
Cancer (from the greek word karkinos meaning crab) is characterized by uncontrolled cell 
proliferation and by the capability of tumor cells to invade neighboring tissues and 
metastasize. There is nowadays wide acceptance that cancer development is a process of 
molecular events involving genetic or epigenetic changes that affect cell to cell signal 
transmission, cell cycle function, genome integrity and angiogenesis. Three types of genes 
are involved in the carcinogenic pathway: tumor suppressor genes, oncogenes and DNA 
repair genes.   
 
Tumor suppressor genes are genes that exert an inhibitory function on cell proliferation. 
The products of these genes play an important role in cell cycle regulation, apoptosis 
control, suppression of growth factors and as negative regulators in signaling pathways. 
The main tumor suppressor genes involved in CRC tumorigenesis are APC, DCC and 
TP53 
57
. Mutations in tumor suppressor genes usually have a recessive effect. Thus, 
according to the classical two-hit hypothesis of Knudson 
58
, both alleles need to be 
knocked out by a mutagenic event in order for the gene function to be lost. The first may 
be a somatic or germline mutation, while the second tends to be a partial or complete 
deletion of the other chromosome, so called loss of heterozygosity (LOH). 
 
Proto-oncogenes/oncogenes are genes that by mutation become activated or 
hyperactivated, thereby promoting a carcinogenic development. The product of these 
genes, called oncogenes after activation, can affect functions such as response to growth 
factors by producing inappropriate stimulatory signals. The most important proto-
oncogene in the tumorigenesis of CRC is KRAS 
57
. Mutations in proto-oncogenes 
typically have a dominant effect, which means that only one of the two alleles needs to be 
mutated. 
 
DNA repair genes are genes involved in preserving the integrity of the genome by 
correcting mistakes that occur during the DNA replication. At least seven mismatch repair 
(MMR) genes are known in humans, the most commonly involved in CRC development 
being MLH1, MSH2, MSH6 and PMS2. The proteins encoded by these genes function by 
recognizing and repairing single mismatched base pairs and nucleotide insertions or 
deletions. A germline mutation in MMR genes or epigenetic silencing by methylation of 
these genes will result in the accumulation of thousands of frameshift mutations in coding 
and non-coding repetitive DNA sequences (so called microsatellites)
59, 60
. 
 
The carcinogenesis of CRC is one of the most well-characterized pathways to malignancy 
in humans. Although the complexity of the molecular events behind this process has 
gradually been unraveled, the multistep model with sequential and additive genetic hits 
presented by Fearon and Vogelstein in 1990 
57
 still holds up (Figure 5). Today, two major 
pathways to the development of CRC are established. However, other routes, such as the 
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serrated/CIMP pathway, have been discovered and cross-talk between the different 
pathways involved in CRC carcinogenesis has been suggested.  
 
Chromosomal instability (CIN) pathway 
This “canonical” pathway is believed to be responsible for 80-85% of all CRCs, including 
tumors in the FAP syndrome, and follows the model outlined by Fearon and Vogelstein. It 
is believed that the majority of CRCs arise from pre-existing adenomas and this model 
correlates the specific sequential genetic events to the evolving morphology in the 
adenoma-carcinoma sequence according to Figure 5. The most frequently observed 
chromosomal losses in CRC are seen in regions 5q, 17p and 18q which harbor the 
important tumor suppressor genes APC, TP53 and DCC. Activation of KRAS is seen in 
about 50% of carcinomas and adenomas greater than 1 cm in size 
61, 62. 
Although the 
proposed order for genetic alterations in Figure 5 exists, the order of these events is not 
invariant. In fact, the accumulation of the multiple genetic hits in both oncogenes and 
tumor suppression genes seems to be most the important 
57
.  
 
         
Figure 5. Molecular alterations in the chromosomal instability (CIN) pathway. Modified from 
Fearon & Vogelstein (1990) and Moran et al (2010). 
 
Microsatellite instability (MSI) pathway 
Microsatellites are short repetitive tandem sequences that are scattered through the human 
genome, both in coding and non-coding sequences. The MSI or mutator pathway, which 
is present in 12-20% of sporadic CRCs and in patients with LS, is characterized by a huge 
accumulation of mutations in these sequences, so called microsatellite instability (MSI) 
60, 
63
. This accumulation of frameshift mutations is caused by a primary defect in the MMR 
genes. The proteins encoded by these genes recognize mismatched bases in DNA during 
replication and are responsible for recruiting the helicase and exonucleases necessary for 
removal of the mismatch. When MMR proteins are functional, errors made by DNA 
polymerase in microsatellite sequences during replication is repaired.  However, tumors 
with a high level of microsatellite instability are characterized by a 100-1000 fold higher 
mutation rate than in normal cells. The MMR genes most frequently associated with MSI 
CRCs are MLH1 (mut L homolog 1, 3p21), MSH2 (mut S homolog 2, 2p22), MSH6 (mut 
S homolog 6, 2p16) and PMS2 (postmeiotic segregation 2, 7p22)
64-67
, while MLH2, 
MLH3, MSH3, PMS1 and Exo1 are believed to be involved to a lesser extent. The MMR 
proteins work in heterodimeric complexes when active in DNA repair (Figure 6) 
68, 69
. 
There is data supporting the idea that loss of MLH1 and MSH2 is associated with 
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complete inactivation of MMR function, whereas defects in the other proteins only cause 
partial MMR deficiency 
70
. 
MMR genes can be silenced either by a germline mutation plus a second hit (most often 
affecting MLH1 or MSH2) as in LS, or by bi-allelic epigenetic silencing through 
hypermethylation of the promotor of MLH1, as in sporadic MSI tumors. Most sporadic 
MSI-H tumors show the CpG methylator phenotype (see below) characterized  
by widespread DNA hypermethylation 
71
. Big cytogenetic abnormalities as in the  
CIN pathway are usually not detected in sporadic MSI-H tumors. Instead, mutations are 
seen in microsatellite sequences in genes associated with CRC, such as TGFRβ2 
(transforming growth factor beta receptor type 2), IGF2R (insulin-like growth factor 
receptor II), BAX (BCL2-associated protein X), APC, β-catenin and MMP-3 (matrix 
metalloproteinase 3) 
72-77
. MSI status of tumors can be determined by using PCR. 
According to international consensus criteria a panel of five microsatellite sequences is 
proposed for defining MSI. The recommended panel consists of two mononucleotide 
repeats and three dinucleotide repeats. Tumors with a high level of microsatellite 
instability (MSI-H) are defined as having instability in two or more markers, whereas 
tumors with low microsatellite instability (MSI-L) have instability in only one marker 
78
. 
Microsatellite stable (MSS) tumors show no instability in any of the five loci. Instability 
is defined as a change in any length due to either insertion or deletion in repeating units in 
a microsatellite within a tumor, compared to normal tissue. An alternative to PCR based 
methods for MSI is immunohistochemical staining for each of the MMR proteins to 
detect loss of expression compared to normal tissue. This method is easy to perform and 
allows for pinpointing of the mutated gene. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The importance of recognizing MSI-H tumors lies in their distinct clinical and 
histopathological features. MSI-H tumors are located predominantly in the right colon and 
are reported to be more frequent in women 
79, 80
. They also typically present with a greater 
depth of invasion but with a lower overall stage 
79
. A better outcome for MSI-H tumors 
(whether sporadic or in LS) compared to MSI-L and MSS tumors has been reported by 
Figure 6. A. A mismatched nucleotide is 
introduced in DNA during a replication error. 
B. The mispaired base is recognized by a 
heterodimeric comlex of MSH2-MSH6 (or 
MSH2-MSH3). The complex binds to the 
mismatched base pair in an ATP dependent 
reaction. C, D A complex of MLH1-PMS2 
binds to DNA and repairs the error. 
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many 
81, 82
. The prognostic advantage of MSI-H seems to be most evident for stage II and 
stage III disease 
82
, but MSI status is considered to be a predictor of favorable outcome 
independent of stage 
83
. MSI-H cancers display enhanced immunogenic properties which 
might contribute to the better outcome. The association between MSI-H and a good 
prognosis is independent of the mechanism behind it (germline mutation or silencing via 
hypermethylation). Interestingly, 5-fluorouracil based chemotherapy does not seem to 
provide a survival benefit among patients with MSI-H tumors, why this type of therapy 
should perhaps be avoided 
82
. The histopathological profile of MSI-H tumors is dealt with 
in Chapter 4.  
 
MSI-L cancers have been considered by some authors to be halfway between MSI-H and 
MSS. However, MSI-L tumors show clinicopathological and molecular characteristics 
more similar to MSS tumors with LOH and KRAS mutations 
84
, why they are usually 
grouped together with these. 
 
Serrated/CIMP pathway 
The characteristic histologic feature of polyps in the serrated group, hyperplastic, sessile 
serrated adenoma and traditional serrated adenoma, is the “saw-toothed” or stellate 
infolding of the crypt epithelium. Studies have shown that serrated polyps, especially 
sessile serrated adenomas, are more frequently associated to cancers that show MSI-H 
than to those that are MSS 
85, 86
. The combination of a cytosine nucleotide followed by a 
guanine nucleotide (CpG dinucleotide) is uncommon in the human genome. However, 
dense clusters of CpG dinucleotides, named CpG islands, are found in the promotor 
region of half of all genes. Aberrant hypermethylation of these promoter islands, so called 
CpG island methylator phenotype (CIMP), has been associated with silencing of tumor 
suppressor genes and subsequent development of cancer 
87
. In serrated adenomas with the 
MSI-H phenotype, such aberrant methylation of MLH1 with loss of its expression is 
frequently noted. Also, in these tumors mutations of the same target genes as those in 
MSI-H cancers, for example IGF2R, BAX and TGFβR2 have also been reported 73, 74, 88. 
Further understanding of the serrated pathway has come from the discovery that 
mutations in the oncogene BRAF (v-raf murine sarcoma viral oncogene homolog B1) 
correlates with CIMP and occurs very early in the serrated pathway. There seems to be a 
synergistic effect of these two genetic events causing further progression of the lesion 
89
. 
Genes related to invasion and metastasis 
The capability of invasion and metastasis in CRC depends on a complex series of events 
including proteolysis of the local extracellular matrix, adhesion, angiogenesis, 
dissemination and cell growth. Several genetic alterations are involved in these processes. 
In the proteolysis step, proteinases such as the metalloproteinases (MMPs) degrade 
extracellular matrix components and enable cancer cells to detach from the primary 
tumor. MMP-7 (matrilysin) is overexpressed in the majority of CRCs and its expression is 
positively correlated with the metastatic potential of the tumor 
90
. Many adhesion 
molecules including cadherins, integrins, VCAM-1 (vascular cell adhesion molecule 1) 
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and CEA (carcinoembryonic antigen) have been identified in CRCs. Cancer cells 
expressing these molecules are more likely to adhere to the extracellular matrix, leading 
to subsequent invasion and metastasis. However, downregulated expression of E-
cadherin, a cell to cell adhesion molecule, is associated with invasiveness and metastatic 
potential of many cancers.   
Angiogenesis is a crucial step in the progression of a tumor and provides a source for 
hematogenous dissemination and metastasis. Potential angiogenic factors include PD-
ECGF (platelet-derived endothelial cell growth factor) and the six VEGF (vascular 
endothelial growth factor) molecules A-F.  VEGF signal transduction involves binding to 
tyrosine kinas receptors, resulting in endothelial cell proliferation, migration, new vessel 
formation and increased vascular permeability. CRCs with increased VEGF expression 
are known to be associated with a poor prognosis 
91
. 
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3. PREDISPOSITION TO COLORECTAL CANCER_   
 
Twin studies have indicated that up to 35% of all CRCs can be ascribed to an inherited 
susceptibility 
8
. The currently known high-risk syndromes such as FAP and LS however 
account for fewer than 5% of all CRC cases, leaving the majority with an unexplained 
genetic background. For individuals from unexplained family clusters with an affected 
first-degree relative, the lifetime risk of CRC is more than twice that of a general 
population 
92
. Some of these cases may be the result of hitherto unexplained highly 
penetrant genetic changes, although most of the inherited susceptibility is believed to  
be the result of common low or moderate risk alleles that act in an additive or 
multiplicative way, or as modifiers of other risk factors. The approximate frequency of 
different types of CRCs in relation to the genetic background in a Swedish population is 
shown in Figure 7 
93, 94
.           
                                 
Figure 7. The genetic background of CRCs in a Swedish population. Modified from Picelli et al 
(2009) and Olsson and Lindblom (2003). 
 
Colorectal cancer syndromes 
Familial adenomatous polyposis (FAP) 
FAP is an autosomal dominant syndrome characterized by the development of hundreds 
to thousands of adenomas throughout the colon and rectum, usually beginning in late 
childhood or adolescence. Because of the large number of polyps, several adenomas will 
inevitably develop into adenocarcinomas usually before the early forties. The penetrance 
of this disease is therefore 100% and the mean age at CRC diagnosis in untreated 
individuals is 40 years. The incidence of FAP is in the range 1: 30.000-7.000 and the 
syndrome accounts for less than 1% of all CRC cases. Apart from CRC, patients with 
FAP frequently develop small intestinal polyps, mainly duodenal adenomas, as well as 
gastric polyps, usually of the fundic gland type. The extra-gastrointestinal manifestations 
include a retroperitoneal or mesenterial fibromatosis called desmoid tumor (10-25% of 
patients), bone lesions such as exostoses and endostoses, dental abnormalities and 
epidermal cysts. Variants of FAP include Gardner’s syndrome, Turcot syndrome and 
attenuated FAP (AFAP) 
3
.  
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A deleterious germline mutation in APC is seen in 95% of patients with classic FAP. In 
all individuals carrying this mutation, development of the syndrome follows the 
occurrence of a second hit which deletes the function of the remaining wild-type gene. 
95% of the germline mutations are nonsense mutations due to insertions or deletions 
leading to an altered reading frame, producing a truncated protein 
95
. The normal function 
of the APC protein as a negative regulator in the Wnt pathway is thereby disturbed 
leading to abnormal signal transduction and activation, as well as impaired cell adhesion 
(see Chapter 2).  
 
Lynch syndrome (LS) 
This syndrome, named after oncologist Henry Lynch, is an autosomal dominant disorder 
causing 1-3% of all CRCs. LS, previously called hereditary non-polyposis CRC 
(HNPCC), is the most common form of hereditary CRC. In contrast to FAP, patients with 
LS present with only a few polyps that within 1-2 years develop into cancer.  Previously 
an average age at CRC diagnosis of 44 years has been reported, although recent 
population based data may suggest a later age of onset. The lifetime risk of developing 
CRC in LS depends on sex, type of gene involved and environmental risk factors and has 
been reported to be 69% for men and 52% for women. LS patients also carry an increased 
risk for cancer in other sites than the large bowel, including the endometrium (20-60% 
lifetime risk and the second most common cancer in LS), ovary, stomach, hepatobiliary 
tract, upper urinary tract, brain and skin. The combination of sebaceous gland tumors and 
LS-type internal malignancies is referred to as the Muir-Torre syndrome 
3
. 
 
Before the discovery of MMR gene mutations as the cause of LS, clinical diagnostic 
criteria (Amsterdam I and II, see Table 1) 
96, 97
, where used to define families with this 
syndrome. However, in about half of the families that fulfilled these criteria neither MSI 
nor an MMR mutation could be found. Today the term LS is reserved for families with an 
identified pathogenic germline mutation in one of the four genes with a verified or 
putative function in MMR: MLH1, MSH2, MSH6 and PMS2 
98
. Deficiency in these genes 
will be manifested as MSI as discussed in Chapter 2. The Bethesda criteria (revised in 
2002) 
99
 were created to select individuals that are suspected to have LS for MSI analysis 
(see Table 1).  
 
Mutations, mostly truncating but sometimes missense, in MLH1 and MSH2 lie behind 
approximately 50% and 40% of LS cases respectively 
100
, while mutations in MSH6 and 
PMS2 are much more uncommon. MSH2 mutations seem to confer a higher risk of 
extracolonic cancers than do MLH1, although there is no clear-cut correlation between the 
involved gene, mutation site or type, and the clinical picture. MSH6 may however be 
associated with an elevated occurrence of endometrial carcinomas 
101
 and an “attenuated” 
type of LS caused by MSH6 mutation and characterized by lower penetrance, has also 
been proposed 
102
. MMR genes behave like tumors suppressors in that heterozygous cells 
can repair DNA normally. Thus, a second hit caused by deletion, mutation or methylation 
of the MLH1 promoter in the wild-type allele is required for tumor development. CRCs in 
LS and the 10-15% of sporadic CRCs that are MSI-H positive display similar 
pathological features. Both show a predilection for the proximal colon (at least 60% of LS 
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cancers), although patients with sporadic MSI-H tumors tend to be older and lack a family 
history of CRC 
103
. 
 
Table 1. Overview of Amsterdam I and II criteria for Lynch syndrome and revised Bethesda 
criteria.   
 
Amsterdam criteria I 
There should be at least three relatives with CRC; all the following criteria should be 
present: 
1. One should be a first-degree relative of the other two 
2. At least two successive generations should be affected 
3. At least one CRC should be diagnosed before the age of 50 years 
4. Familial adenomatous polyposis should be excluded 
5. Tumor should be verified by pathological examination 
Amsterdam criteria II 
There should be at least three relatives with a Lynch syndrome-associated cancer (CRC, 
cancer of the endometrium, small bowel, ureter or renal pelvis); all of the following criteria 
should be present: 
1. One should be a first-degree relative of the other two 
2. At least two successive generations should be affected 
3. At least one CRC should be diagnosed before the age of 50 years 
4. Familial adenomatous polyposis should be excluded in the CRC case(s) if any 
5. Tumors should be verified by pathological examination 
Revised Bethesda criteria 
1. CRC diagnosed in a patient less than 50 years of age 
2. Presence of synchronous, metachronous colorectal, or other Lynch syndrome-related 
tumors* regardless of age 
3. CRC with MSI-H phenotype** diagnosed at less than 60 years of age 
4. Patient with CRC and a first-degree relative with a Lynch syndrome-related tumor, 
with one of the cancers diagnosed before the age of 50 years 
5. Patient with CRC with two or more first- or second-degree relatives with a Lynch 
syndrome-related tumor, regardless of age 
CRC, colorectal cancer 
*  Lynch syndrome-related tumors include colorectal, endometrial, stomach, ovarian, 
pancreas, ureter, renal pelvis, biliary tract and brain-tumors, sebaceous gland adenomas, 
keratoacanthomas and carcinoma of the small bowel 
** Tumor infiltrating lymphocytes (TILs), Crohn-like peritumoral lymphocytic reaction, 
mucinous/signet-ring differentiation or medullary growth pattern 
 
 
Familial colorectal cancer type X 
About half of families fulfilling the Amsterdam I criteria show no evidence of a heritable 
MMR defect, either by gene sequencing or tumor phenotyping for MSI. In addition, 
individuals in theses pedigrees display only a modest increase in the incidence of CRC 
and no increased risk of other types of LS-related cancers. The mean age of the patients in 
this Amsterdam I-positive MSI-negative group, coined familial colorectal cancer type X 
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(FCCTX), is also higher than in LS patients (60.7 versus 48.7 years) 
104
. Also, in contrast 
to LS, tumors in FCCTX tend to be left-sided and show a slower adenoma-carcinoma 
progression rate 
105
. Very little has been elucidated about the mechanisms behind this 
form of familial CRC. It has been suggested that this is a heterogenous group comprised 
of (1) some cancers aggregating by chance alone, (2) some aggregation related to shared 
lifestyle factors and (3) some yet to be defined genetic changes 
104
.  
 
Other colorectal cancer syndromes and entities 
MUTYH-associated polyposis, Peutz-Jeghers syndrome, juvenile polyposis syndrome, 
Cowden syndrome and hereditary mixed polyposis syndrome are all uncommon entities 
for which the genetics at least in part have been unraveled. There is, however, support for 
the hypothesis of additional high-risk monogenic syndromes for which the molecular 
background has not yet been defined. In a Swedish survey the frequency of non-FAP non-
LS families having three or more first-degree relatives with CRC in at least two 
generations, i.e. showing a dominant pattern, was 1.9%.  In addition, 8.3% of CRC cases 
came from families with two affected first- or second-degree relatives, where the risk for 
CRC is lower 
93
. There is also evidence for rectal cancer as separately inherited entity 
106
 
and a serrated polyposis syndrome (Jass syndrome) has been described 
85, 86
. 
The search for low-risk genetic variants 
Since the known high-risk syndromes only account for a small minority of CRC cases 
there has been an intensified search for low-penetrance genetic variations that probably 
underlie the major part of the hereditary disposition and together with environmental 
interactions are responsible for CRC as a complex disease.  
 
Linkage analysis has been the classic method of choice for finding genes causing 
monogenic Mendelian diseases, such as in FAP and LS. In this method a number of DNA 
markers of known position are tested in family members segregating the disease. The 
closer two loci are on a chromosome the less likely they will be separated by 
recombination. By identification of DNA markers that co-segregate with the disease more 
often than expected by random segregation, the chromosomal region that harbors the 
responsible gene is located.  The use of linkage analysis in the search for new syndromes 
in non-FAP non-LS families has yielded divergent results and loci associated to CRC 
have been suggested on chromosome 1, 3, 6, 7, 9, 11, 14, 15, 17 and 21. The loci on 
chromosome 3, 9 and 15 have been replicated in independent studies 
107-109
. Linkage 
analysis however requires the use of large families and clearly defined genotypes. The 
method also has low power in detecting weak effects and high sensitivity to locus 
heterogeneity. Thus, when the penetrance of the disease is low the locus is usually 
difficult or impossible to identify by linkage since too many unaffected individuals who 
carry the allele will confound the calculations 
110
. One possible way to minimize the 
problem with locus heterogeneity might be to subgroup the families according to 
differences in phenotype (such as tumor morphology) or according to the degree that they 
are affected. 
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Genome-wide association studies 
In the past few years the search for novel susceptibility loci has been boosted by the 
emergence of genome-wide association studies (GWAS) and the use of single nucleotide 
polymorphism (SNPs). GWAS allows for the examination of genetic variants in a large 
population by comparing the frequency of an allele marker (usually a SNP) in a set of 
unrelated affected individuals (cases) with the frequency in a set of unaffected individuals 
(controls). Allelic association is present if the co-existence of a specific allele marker and 
the disease exceeds the expected occurrence based on random segregation. The term 
linkage disequilibrium is used to refer to allelic association between two linked loci. An 
association between the tested marker and the disease (phenotype) can result either from 
linkage disequilibrium between the marker and a closely located susceptibility gene or 
from a direct biological effect of the marker allele itself. The general rule of thumb is that 
the stronger the allelic association, the closer the marker is to the disease locus. 
Commonly used measures for association are the relative risk and odds ratio (OR) 
110
.  
 
There are however problems with the use of association analysis in genomic scanning. 
First, there is the difficulty with multiple comparisons when so many tests are performed, 
because false-positive results are likely to occur by chance alone unless the usual 
significance levels (0.05 or 0.01) are modified. It is not clear what the appropriate 
correction should be since it depends on the underlying relationship between the markers, 
but typically the p-values must be very low (10
-7
 or 10
-8
) to be considered significant in 
relation to the huge number markers (SNPs) that may be tested. Secondly, the association 
analysis rests solely on the assumption that some level of linkage equilibrium exists. 
Susceptibility alleles arising from frequent mutations or arising in genomic regions with 
very high recombination rates will have little or any detectable linkage disequilibrium. 
Thirdly, variables such as age, sex and the geographical or ethnical background of the 
population could potentially confound the results. Allelic association is population 
specific and special populations such as isolated or inbred populations can be especially 
useful in mapping complex traits 
110
. The idea is that genetically isolated populations will 
have fewer genes contributing to a disease trait and therefore the effect of each remaining 
gene will be easier to detect. The advantage of the special population in its power to 
detect linkage however comes at the potential cost of specificity. If one or several 
susceptibility loci are detected, the effect of this gene or genes may be limited to the 
special population. However, many GWAS follow a setup where the first analysis in a 
discovery cohort is followed by validation of the most significant markers in an 
independent replication cohort 
111-113
. 
 
SNPs 
90% of all allelic differences existing within the human genome can be attributed to 
SNPs, which are nucleotide sequence variations in a single base pair between individuals 
or between the paired chromosomes. Usually SNPs have only two alleles and within a 
population SNPs can be assigned a major and minor allele frequency depending on which 
allele is the most or least frequent. The dbSNP database (www.ncbi.nlm.nih.gov/ 
SNP/index.html) currently contains 10.4 million human SNPs which have been 
condensed into a non-redundant set of 4.8 million validated SNPs, yielding a SNP density 
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of 1 per 1.3 kb 
110
. SNPs localized within a coding region have the greatest potential to 
affect the structure and function of a gene. Less than half of SNPs localized to such 
regions result in no change in the amino acid sequence because of codon redundancy 
(synonymous change), while the rest result in an amino acid alteration (non-synonymous 
change). Most SNPs are however located in non-coding regions such as introns, flanking 
sequences and splice sites, although effects on splicing, folding of mRNA and promoter 
function of these “non-coding” SNPs have been described 110. Many different platforms 
have been developed for SNP analysis based on four basic allele-specific assays: (1) 
hybridization with allele-specific probes, (2) oligonucleotide ligation, (3) single-
nucleotide primer extension and (4) enzymatic cleavage. Many of these techniques have 
been automated in commercial systems, including colorimetric microtiter-plate-based 
assays and microarray chips.   
 
SNPs and colorectal cancer 
The implementation of GWAS performed with SNP chips has led to the discovery of 
several susceptibility loci for CRC, some of which have been replicated in independent 
studies. A list of SNPs found, their locus and associated gene (if detected) is presented in 
Table 2. Most of these detected SNP variants confer an OR for CRC in the range 0.8 
(some exert a protective effect) to 1.4 and are believed to be responsible for about 6% of 
the excess familial risk 
113
. 
 
The first locus identified was 8q24 where the most significant SNP rs6983267 has been 
replicated in several studies 
111, 114, 115
. This SNP maps close to the oncogene MYC, which 
is regulated by the Wnt-signaling pathway. Recently a study has reported that the risk 
genotype (GG) at this SNP affects the binding site for TCF4 (transcription factor 4) so 
that the transcription of MYC is upregulated 
116
. Another locus is 18q.21.1 where the SNP 
rs4939827 maps to SMAD7, an intracellular antagonist of TGFβ signaling 112, 117. The 
SNP rs3802842 on 11q23 is located close to a gene called POU2AF1 which encodes a 
transcription factor. This SNP shows substantial population-specific differences in CRC 
risk. Both rs4939827 and rs3802842 show a higher risk for rectal cancer than for colon 
cancer 
117
.  The locus 15q13.3-q14, previously linked to hereditary mixed polyposis 
syndrome in individuals of Ashkenazi Jewish descent, might also harbor a low-risk 
variant that affects the GREM1 (gremlin 1) gene which also involved in the TGFβ 
pathway 
118, 119
. A meta-analysis of GWAS has identified 14q22.2 as a risk locus where 
the SNP rs 4444235 maps close to the transcription start site of the gene BMP4 encoding 
bone morphogenic protein 4 
113
. BMP signaling inhibits intestinal stem cell self-renewal 
through suppression of the Wntβ-catenin signaling. The SNPs rs 10411210 and 
rs7259371 contain the RHPN2 (Rho GTPase binding protein 2) gene involved in the 
regulation of actin cytoskeleton and cell motility 
113, 120
 and rs9929218 maps to the CDH1 
(cadherin 1) gene affecting the β-catenin T-cell transcription factor pathway 113, 121. On 
8q23 there is no certain disease causing gene, but the SNP rs16892766 is in linkage 
disequilibrium with a region that includes EIF3H, a gene involved in cell-growth and 
viability 
122
. There are no evident protein-coding sequences in the vicinity of rs10795668 
on 10p14 
122
. The same is true for the SNPs rs961253 & rs355527 on 20p12.3, although 
the BMP2-gene is located 342 kb telomeric to this site 
113
. rs 7197259 on 9p24 is not 
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located within any gene. However, there are four genes nearby, none of which have been 
implicated in CRC so far 
111, 123
. In a replication study of all of the above mentioned SNPs 
in Swedish cohort within the Swedish Low-Risk Colorectal Cancer study (see Chapter 7), 
five showed statistically significant ORs similar to previous reports: the SNPs on 8q23.3, 
8q24.21, 10p14, 15q13.3 and 18q21.1. The loci on 11q23, 16q22.1, 19q13.1 and 20p12.3 
showed weak trends towards association, but 9p24 and 14q22.2 were not confirmed. In 
addition, four correlations between SNPs and phenotypes were found: the G allele of 
rs6983267 showed an association to older age, the G allele of rs1075668 to younger age 
and sporadic cases, and the T allele of rs10411210 to younger age 
124
. 
 
Table 2. CRC loci identified by genome-wide association studies (GWAS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP ID Locus Gene 
rs6983267 8q24.21 MYC? 
rs16892766 8q23.3     ? 
rs10795668 10p14     ? 
rs4939827 18q21.1 SMAD7 
rs3802842 11q23.1 POU2AF1? 
rs4779584 & rs10318 15q13.3 GREM1 
rs961253 & rs355527  20p12.3     ? 
rs4444235  14q22.2 BMP4 
rs10411210 & 7259371 19q13.1 RHPN2 
rs9929218 16q22.1 CDH1 
rs719725 9p24.1     ? 
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4. PATHOLOGY______________________________________    
 
CRC is a malignant tumor originating in the epithelium of the colon or rectum. More than 
90% of CRCs are adenocarcinomas which usually develop from the precursor lesion 
adenoma. The definition of carcinoma in colon and rectum (unlike in the rest of the 
gastrointestinal tract) requires invasion through the lamina muscularis mucosae into the 
submucosa. Although lymphatic vessels are present in the colorectal mucosa metastatic 
spread is not believed to occur unless the muscularis mucosae is breached 
3
. 
 
Macroscopic features 
CRCs can grow in a polypoid (exophytic) fashion into the lumen or, more commonly, as 
an ulcerative (endophytic) lesion infiltrating into the wall (Figure 8). Annular growth with 
circumferential involvement and stenosis of the lumen is also common but diffusely 
infiltrative growth resembling linitis plastica of the stomach is rarely seen. Although there 
is significant overlap of features, carcinomas proximal to the splenic flexure tend to grow 
as exophytic masses while those distally in colon and rectum usually are more endophytic 
and annular. Most CRCs are homogenous and grey-white on the cut surface, often with 
necrosis, although mucinous tumors may be gelatinous. Sometimes penetration or 
napping of the serosal surface or overgrowth on adjacent organs may be detected 
macroscopically 
3
. 
 
         
     
Figure 8. Colonic carcinomas after formalin fixation. A. Polypoid tumor of the hepatic flexure. B. 
Ulcerated tumor of the sigmoid covering a large part of the circumference.   
 
A B 
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Microscopic features 
The majority of CRCs are typical adenocarcinomas composed of moderate to large sized 
irregular glands often containing necrotic debris in the lumen. The tumor cells are usually 
clearly atypical although still cylindrical and somewhat resembling the normal colonic 
mucosal cells. Often there is ulceration as well as some degree of desmoplastic stromal 
reaction and inflammatory response around the tumor.  Perineural, lymphatic and venous 
invasion is not uncommon. At the periphery of the tumor sometimes a remnant of a pre-
existing adenoma may be found. As stated above, the diagnosis of CRC requires invasion 
through the lamina muscularis mucosae. For lesions confined to the mucosa the term 
intramucosal carcinoma has been applied although this is equivalent to high-grade 
dysplasia. 
Grading 
Traditionally CRCs have been graded as well-, moderately or poorly differentiated on the 
basis of glandular formation according to Table 3. This classification is still the one 
widely used among Swedish pathologists. Recently a two-tiered grading system with only 
low-grade and high-grade has been proposed by the WHO, because of greater 
reproducibility and the similar clinical behavior of well- and moderately differentiated 
carcinomas 
3
. Undifferentiated carcinoma (grade 4) is a term of exclusion reserved for 
carcinomas that show no morphological or immunohistochemical evidence of glandular 
formation, mucin production, or neuroendocrine, squamous or sarcomatoid 
differentiation. Grading is based on the least differentiated component of tumor, 
disregarding the deep invading front. 
 
Table 3. Criteria for histological grading of colorectal adenocarcinomas (modified after WHO, 
2010). 
   
Criterion Differentiation Numerical grade* Descriptive grade 
>95% gland 
formation 
Well-differentiated              1            Low 
50-95% gland 
formation 
Moderately 
differentiated 
             2            Low 
0-49% gland 
formation 
Poorly differentiated              3            High 
    
*The category ”undifferentiated carcinoma” (grade 4) is reserved for carcinomas with no gland 
formation, mucin production or neuroendocrine, squamous or sarcomatoid differentiation.  
         
Specific features in CRC 
Crohn-like peritumoral lymphocytic reaction is defined as the presence of nodular 
aggregates of mainly B-lymphocytes deep to the advancing tumor margin, usually located 
in the lamina muscularis propria or in the pericolic fibroadipose tissue. This reaction 
represents a host immune response towards the tumor and has derived its name from the 
resemblance to transmural lymphocytic aggregates, a hallmark of Crohn’s disease. The 
presence of Crohn-like reaction has been linked to improved patient survival in some 
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studies 
125,126
 and is one of the characteristics of MSI-H tumors. At least three nodular 
aggregates of lymphocytes within a single x4 field deep to the advancing tumor margin 
has been used as a definition of this feature 
126
. 
 
 
Figure 9. CRCs of different grades. A. Well-differentiated B. Moderately differentiated C. Poorly 
differentiated. Hematoxylin & eosin (H &E) staining, x40. 
 
Tumor infiltrating lymphocytes (TILs) are intraepithelial, mainly cytotoxic, T-
lymphocytes that are found within the tumor tissue. An abundance of TILs have been 
associated with improved clinical outcome 
127, 128
 and TILs are one of the most sensitive 
and specific features in predicting MSI-H 
129
.  The exact mechanism of TIL accumulation 
and its association to improved outcome has not been elucidated, although the adaptive 
immune system may play a role in suppressing tumor progression. TILs may reflect 
specific molecular alterations associated with indolent tumor behavior and it has been 
suggested that truncated peptides produced by frameshift mutations due to MSI may be 
immunogenic and contribute to the host immune response. It has also been proposed that 
MSI-H CRCs are less able to express functional Fas ligand and thereby less successful in 
killing lymphoid cells by Fas mediated apoptosis 
129
. Several definitions of a high level of 
TILs have been used such as a cut-off value of 0.7, 2 or >3 TILs per high power field, or 
≥5 TILs/100 cancer cells. 
Desmoplasia, i. e. a hypocellular intense fibrous reaction around infiltrating tumor tissue, 
is often seen in CRC. There are conflicting reports regarding the role of stromal response 
in cancer development. It has been argued that it limits tumor aggressiveness and could 
represent an attempt by the host to seal off the tumor, which is also supported by some 
studies that show a survival benefit in cases with desmoplasia 
130
.  However, a fibrotic 
response could also favor the tumor by neovascularization and preventing access to host 
lymphocytes, macrophages and other immune regulatory cells. Focus has also been drawn 
not only to the amount of fibrosis, but also to its qualitative nature. In a study by Ueno et 
al, an immature fibrous stroma consisting of randomly oriented keloid-like collagen 
bundles in a myxoid tissue was a negative prognostic factor, as opposed to a denser 
mature collagen stroma 
131
.  
 
 28 
Dirty necrosis or garland necrosis is the presence of large amounts of cell detritus and 
inflammatory cells within the glandular lumina. It is often considered a characteristic of 
CRC. The absence of this feature has however been described as a marker for MSI-H 
tumors, especially if it is combined with mucinous differentiation and a high number of 
TILs 
79, 132
. 
 
Vascular invasion, both venous and lymphatic, has been found to be an independent 
prognostic factor in both univariate and multivariate analyses 
91, 133-135
. In some studies the 
location of vascular invasion in extramural veins has been of prognostic value 
136
. The 
diagnosis of intravascular tumor growth is often difficult to make because fixational 
artefacts with retraction of tumor strands in fibrotic tissue can mimic vascular invasion. 
The frequency of vascular invasion is reported to vary from 10 to 89.5% 
137
, with false-
negative rates between 10.5 and 29.6% if only hematoxylin & eosin (H & E) staining is 
used 
138
. The frequency is also influenced by the number of blocks taken and if tangential 
sectioning is performed. The assessment of vascular invasion can be improved with 
immunohistochemical staining for endothelial markers such as CD31 or CD34, and 
lymphatic spaces can be differentiated from venous by their positivity for the 
immunomarker D2-40.  
 
Perineural invasion is defined as tumor cells infiltrating underneath the perineurium at 
the invasive margin of the tumor or deep to it. In a number of multivariate studies this 
feature has been shown to be an independent indicator of poor prognosis 
139
.  
 
Budding is defined as the detachment of single isolated cancer cells or a cluster of up to 
four cells in the stroma at the invading front of the tumor. This feature, which represents 
dedifferentiation of the tumor and the first step of invasion and metastasis, has been 
shown to be an independent adverse prognostic factor 
140
. Attempts to quantify budding 
have been made and immunohistochemical staining for cytokeratins can be used to 
highlight this feature. 
 
Tumor margin configuration has been reported to have prognostic significance that is 
independent of stage. An infiltrative irregular pattern of growth is an adverse prognostic 
factor as opposed to a circumscribed smooth-pushing pattern 
139, 141
. However, 
interobserver variability among pathologists in evaluating this feature is high with only 
fair agreement as to what should be called an infiltrating growth pattern 
142
. 
 
Immunohistochemistry 
Most CRCs are negative for cytokeratin 7 (CK7) but positive for cytokeratin 20 (CK20). 
However 10% of CRCs are extensively positive for CK7 and approximately 5% are 
negative for CK20. CK7 staining is increased and CK20 staining is decreased in MSI-H 
tumors. CDX2 (caudal-type homeobox protein 2) stains 98-100% of all CRCs. Expression 
of CDX2 is not associated with MSI status. In addition, CRCs are usually positive for 
CK8, CK18, CK19 (low molecular weight cytokeratins) and 40% stain for MUC2 
(intestinal type of mucin) 
143, 144
. 
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Figure 10. Specific features of CRCs: A. Crohn-like peritumoral lymphocytic reaction (x20). B. 
Tumor infiltrating lymphocytes (TILs) in a poorly differentiated tumor with medullary features 
(x200). C. Desmoplasia (x100). D. Dirty necrosis (x100). E. Vascular (venous) invasion (x25). F. 
Perineural invasion (x100). G. Budding (x200). H. Circumscribed tumor margin (x40). J. 
Infiltrative tumor margin. (x25). H & E staining. 
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Special variants of CRC 
 
Mucinous adenocarcinoma 
This type of CRC is composed to >50% of pools of extracellular mucin that contain 
malignant epithelium in the form of acinar structures, strips of tumor cells or individual 
tumor cells (Figure 11A). Signet-ring cells may be seen. 10-20% of CRCs are described 
as mucinous and these tumors have poorer 5-year survival compared to non-mucinous 
CRCs 
145
, although results are conflicting 
146
. According to WHO (2010) the 
differentiation of a mucinous cancer is determined by the level of maturation of the 
malignant epithelial cells, but according to Swedish consensus criteria and older WHO 
criteria (2000) mucinous cancers and signet-ring cell cancers have by definition been 
classified as poorly differentiated. Many mucinous carcinomas are however MSI-H 
positive and thereby low-grade 
147
. Carcinomas with <50% mucinous areas are 
categorized as having a mucinous component 
3
. 
 
Signet-ring cell carcinoma 
This type of CRC is sometimes considered a subtype of mucinous carcinoma and is 
defined by >50% tumors cells with a prominent intracytoplasmatic vacuole and typically 
displacement of the nucleus, so called signet-ring cells (Figure 11B). These cells can 
occur floating in pools of free mucin or infiltrating in a diffuse manner within a fibrous 
stroma (linitis plastica-pattern). Carcinomas of the signet-ring cell type comprise only 0.7-
2.6% of all CRCs.  Compared to both conventional adenocarcinomas and mucinous 
adenocarcinomas without signet-ring cells, they tend to present at a higher T-stage and 
with a higher number of lymph node metastases. They also show a poorer outcome with a 
higher rate of distant recurrence and decreased survival 
148
. Some signet-ring cancers are 
however MSI-H positive and thereby low-grade. Signet-ring cell carcinomas develop 
through a separate genetic pathway showing disruption of the E-cadherin/β-catenin 
complex involved in cell to cell adhesion. A different pattern of alterations from 
conventional colorectal adenocarcinomas has also been shown in growth kinase-related 
oncogenes (KRAS, BRAF), tumor suppressor genes (TP53, TP16), gene methylation and 
COX-2-expression 
148, 149
. 
 
 
Figure 11. A. Mucinous adenocarcinoma (x25). B Signet-ring cell carcinoma (x200) H & E 
staining. 
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Medullary carcinoma 
This rare tumor (0.03% of all surgically removed CRCs) is made up of sheets of 
undifferentiated epithelial cells with vesicular nuclei, prominent nucleoli, abundant pink 
cytoplasm and a conspicuous element of TILs. Although morphologically similar to 
poorly differentiated adenocarcinomas these tumors display a distinct clinical behavior. 
They are more common in older women, more common in right than in left colon, less 
likely to show lymph node metastases and generally carry a better prognosis. Medullary 
carcinomas are associated to MSI-H in most cases 
150
. 
 
Other rare variants 
Serrated adenocarcinomas are architecturally similar to sessile serrated polyps with 
stellate or saw-tooth glands. These tumors can be MSI positive or show BRAF mutations 
and CpG island hypermethylation. Adenocarcinomas with neuroendocrine differentiation 
occur, as well as pure neuroendocrine tumors and carcinomas. Cribriform comedo-type 
adenocarcinoma, micropapillary adenocarcinoma, adenosquamous carcinoma and spindle 
cell carcinoma are unusual variants. Undifferentiated carcinoma is described above 
3
. 
 
Morphology of MSI-H positive tumors 
 
Since the beginning of the 1990s when MMR-deficient tumors and MSI were described it 
has been recognized that these tumors show a distinct phenotype. Clinicopathological 
findings that have been associated with MSI-H positive CRCs (either sporadic or in LS) 
are proximal anatomical location, multiple cancers, poor differentiation (including 
medullary type), mucinous differentiation (including signet-ring cell carcinoma), 
histologic heterogeneity (i.e. at least two distinct growth patterns), Crohn-like peritumoral 
lymphocytic reaction, TILs, absence of dirty necrosis and circumscribed tumor  
margin 
79, 103
. Several reports however point out TILs as the best morphological biomarker 
of MSI-H tumors 
79, 80, 129
. In one study a cut-off of >2 TILs per high-power field resulted 
in 90% sensitivity and 77% sensitivity for MSI-H. The sensitivity was increased to 100% 
by the addition of two other features: any amount of mucinous differentiation and the 
absence of dirty necrosis 
79
. The Bethesda criteria (revised in 2002), which are designed 
to identify individuals at risk for LS, recommend MSI testing of tumors showing TILs, 
Crohn-like peritumoral lymphocytic reaction, mucinous/signet-ring differentiation or 
medullary growth pattern in individuals less than 60 years 
99
. 
 
Immunohistochemistry of MSI-H tumors 
Immunohistochemistry for MMR proteins shows good correlation to PCR for MSI why 
this method is nowadays widely used in the detection of MMR defect tumors. Staining for 
the most commonly affected MMR proteins MLH1, MSH2, MSH6 and PMS2 will show 
lack of staining in tumor nuclei compared to normal tissue in the case of an MMR-
deficient CRC. Studies have shown both high sensitivity (92-92.3%) and specificity 
(99.8-100%) for immunohistochemistry 
151, 152
. The advantage of immuno-histochemistry 
over PCR-MSI is that it can pinpoint the mutated gene, although there is a risk of missing 
a small proportion (8%) of MSI-H tumors that show normal expression of a protein 
which, however, is non-functional due to truncating or missense mutations 
152
. 
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Staging 
 
CRCs can progress with local invasion or show lymphatic or hematogenous spread. 
Colonic carcinomas may after growing through lamina muscularis propria extend directly 
to the serosal surface with peritoneal carcinomatosis. Perforation can occur and the tumor 
may become adherent to adjacent structures or infiltrate directly into adjoining organs. 
Advanced rectal cancers can infiltrate into pelvic structures such as the vagina or urinary 
bladder 
3
. Originally it was believed that CRCs follow an orderly progression from local 
tumor invasion to subsequent lymphatic or hematogenous spread after penetrating the 
intestinal wall. However, today it is known that some tumors show lymph node 
metastases or develop distant disease although they have not penetrated the bowel wall. 
The liver is the most common site for hematogenous spread of CRC, occurring in in about 
50% of cases, and the lung is the second most common. Tumor spread to other sites in the 
absence of lung or liver metastases is uncommon 
145
. 
 
All staging systems for CRC, including the original classification for rectal cancer by 
Cuthbert Dukes as well as the modified by Astler-Coller, are based on the extent of tumor 
spread through the wall and the presence of lymph node or distant metastases. The 
systems mentioned above are now replaced by the TNM classification 
153
 which forms the 
base for the staging system proposed by American Joint Committee on Cancer and the 
International Union Against Cancer (AJCC/UICC¸ see Tables 4 and 5). In addition to the 
TNM variables there are optional descriptors L, V and Pn for lymphatic, venous and 
perineural invasion. The prefix p in pTNM is used to indicate pathological, as opposed to 
clinical or radiological, assessment. The prefix y as in ypTNM signals that the 
classification is performed during or following multimodality therapy such as 
preoperative radiochemotherapy. In Sweden the optional subclassification of T3 tumors 
into a through d is used (see Table 6).  
 
In general, all lymph nodes in a surgical specimen of CRC are sampled by the pathologist. 
However it has been shown that at least 12 to 15 lymph nodes must be examined to 
accurately predict regional lymph node negativity (N0) 
154
. For this reason it has been 
postulated that 12 lymph nodes be considered the minimum acceptable harvest.   
 
Prognostic factors and features 
 
Stage, i.e. the pTNM classification, is the strongest prognostic factor for CRC. However, 
features with adverse effect on outcome include bowel obstruction or perforation, 
extensive circumferential tumor involvement, poor differentiation and signet-ring cell 
carcinomas (with exception for MSI-H tumors), infiltrative tumor margin, budding and 
invasion in lymphatic, venous or perineural spaces. A short distance between the resection 
margin and tumor and incomplete excision with residual tumor also carry an adverse 
prognosis 
3
. CRM involvement in rectal cancer may be the single most critical 
pathological factor in predicting local recurrence 
155
 and has also been shown to predict 
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distant recurrence and overall survival 
139
. Size is of no prognostic significance in  
CRC 
137
. Features with positive effect on outcome are signs of favorable host response 
such as TILs and Crohn-like peritumoral lymphocytic reaction as well as reactive lymph 
nodes.   
 
Several potential molecular or immunohistochemical prognostic or predictive markers 
have been described in the literature but none has yet been introduced in routine practice.  
MSI-H has however proved to be a sign of favorable outcome (hazard ratio about 0.65) 
according to previous discussion. Among other proposed biomarkers are 18q LOH/DCC 
and mutation of KRAS and BRAF 
156
. Recently the immunohistochemical expression of 
ezrin, a molecule involved in plasma membrane stabilizing as well as membrane receptor 
function, has been reported to predict time to local recurrence in rectal cancer 
157.
  
Table 4. TNM (7
th
 edition) classification for carcinomas in colon and rectum.  
 
 Primary Tumor 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis¹ Carcinoma in situ: intraepithelial or invasion of lamina propria 
  
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades subserosa or into non-peritonealized 
pericolic or perirectal tissues 
T4 Tumor directly invades other organs or structures 
 and/or perforates visceral peritoneum 
T4a    Tumor perforates visceral peritoneum 
T4b    Tumor directly invades other organs or  
           structures ², ³ 
Notes:      1. Tis includes cancer cells confined within the glandular 
basement membrane (intraepithelial) or mucosal lamina 
propria (intramucosal) with no extension through the 
muscularis mucosae into the submucosa. 
2. Direct invasion in T4b includes invasion of other organs or  
segments of the colorectum by way of the serosa, as 
confirmed on microscopic examination, or for tumors in a 
retroperitoneal or subperitoneal location, direct invasion 
of other organs or structures by virtue of extension beyond 
the muscularis propria. 
   3. Tumor that is adherent to other organs or structures, 
macroscopically, is classified cT4b. However, if no tumor is 
present in the adhesion, microscopically, the classification 
should be pT1-3, depending on the anatomical depth of wall 
invasion. 
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N Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
 N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c  Tumor deposit(s), i.e. satellites*, in the 
         submucosa, or in non-peritonealized  
         pericolic or perirectal soft tissue without 
         regional lymph node metastasis  
N2 Metastasis in 4 or more regional lymph nodes 
 N2a  Metastasis in 4-6 regional lymph nodes 
N2b  Metastasis in 7 or more regional lymph 
          Nodes 
Note:      * Tumor deposits (satellites), i.e. macroscopic or 
microscopic nests or nodules, in the pericolorectal 
adipose tissue’s lymph drainage area of a primary 
carcinoma without histological evidence of residual 
lymph node in the nodule, may represent discontinuous 
spread, venous invasion with extravascular spread  
(V1/V2) or a totally replaced lymph node (N1/N2).  
If such deposits are observed with lesions that would 
otherwise be classified as T1 or T2, then the T  
classification is not changed, but the nodule(s) is 
recorded as N1c. If a nodule is considered by the 
pathologist to be a totally replaced lymph node 
(generally having a smooth contour), it should be 
recorded as a lymph node and not as a satellite, 
and each nodule should be counted separately as a 
lymph node in the final pN determination. 
 
 
M Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
 M1a Metastasis confined to one organ (liver, 
         lung, ovary, non-regional lymph node(s)) 
M1b Metastasis in more than one organ or 
         the peritoneum  
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Table 5. Staging of colon and rectal cancer (TNM, 7
th
 edition).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Optional subclassification of T3 tumors. 
 
Stage 0 Tis N0 M0 
Stage I T1, T2 N0 M0 
Stage II T3, T4 N0 M0 
Stage IIA T3 N0 M0 
Stage IIB T4a N0 M0 
Stage IIC T4b N0 M0 
Stage III Any T N1, N2 M0 
Stage IIIA T1, T2 
T1 
N1 
N2a 
M0 
M0 
Stage IIIB T3, T4a 
T2, T3 
T1, T2 
N1 
N2a 
N2b 
M0 
M0 
M0 
Stage IIIC T4a 
T3, T4a 
T4b 
N2a 
N2b 
N1, N2 
M0 
M0 
M0 
Stage IVA Any T Any N M1a 
Stage IVB Any T Any N M1b 
T3 Tumor invades subserosa or into non-peritonealized 
pericolic or perirectal tissues 
 T3a  Invasion < 1mm into subserosa or non- 
         peritonealized pericolic or perirectal tissues 
T3b  Invasion 1-5 mm into subserosa or non- 
         peritonealized pericolic or perirectal tissues 
T3c  Invasion 5-15 mm into subserosa or non- 
         peritonealized pericolic or perirectal tissues 
T3d  Invasion > 15 mm into subserosa or non- 
         peritonealized pericolic or perirectal tissues 
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5.CRC IN RELATION TO PATIENT CHARACTERISTICS  
CRC and sex 
 
Studies of CRC have shown female patients to be older and to have more proximal and 
poorly differentiated tumors than males 
158, 159
, as well as more MSI-H tumors 
160
. Two 
retrospective analyses have also reported more advanced stages of cancer in women 
compared to men 
158, 161
. The majority of studies that have assessed sex and overall 
survival have reported no significant associations 
162
. However in one study, women aged 
50 years and above had poorer cancer-specific survival than men independent of age, 
emergency surgery, site, grade and stage, while young women (below 50 years) had a 
significantly better overall survival compared to young men 
159
. The survival advantage of 
young premenopausal women has been proposed to be due to the protection conferred by 
estrogen, which is lost in postmenopausal women 
159
. 
 
There is clinical evidence that estrogen protects against the development of CRC. 
Hormone replacement therapy reduces CRC mortality and parity has been inversely 
associated to the rate of CRC 
160
. The way by which estrogen prevents the development of 
CRC is complex and has not been fully elucidated, although different mechanisms have 
been proposed.  
 
CRC and age 
 
Approximately 8 % of all CRCs occur in persons younger than 50 years and 2-3 % in 
persons younger than 40 years 
163
. Studies of the clinicopathological profile of CRC in 
relation to age have shown contradictory results. According to some studies patients 
younger than 50 years present with less localized and more distant disease (i.e. higher 
stage), as well as a higher rate of poorly differentiated tumors 
163
. There is no definite 
explanation for this, but it is possible that that young patients present with later disease 
because they are not screened or because of delay in patient presentation or lack of 
awareness of the disease, both among patients and physicians. They may also be at higher 
risk because of a higher prevalence of conditions predisposing them to CRC such as a 
family history of the disease. However, one cannot rule out that young patients present at 
a higher stage because of tumors that per se, because of genetic or other biological 
reasons, are more aggressive. On the other hand, some studies have shown that stage at 
presentation and survival figures for young patients are comparable to those reported in 
older age groups 
164
. 
 
Mucinous tumors have been described to be up to four times more frequent in young 
patients compared to elderly, comprising 20 % of all CRCs in the young group. This type 
of tumor in the young has been associated with an increased risk of local recurrence 
164
. A 
high number of lymph node metastases, vessel invasion, and infiltrating tumor margin are 
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reported to be more common among patients below 50 years. These findings are also in 
line with a more aggressive histopathological profile. In addition, both young men and old 
women show a relatively high frequency of right-sided tumors 
165
. 
 
CRC and location 
 
The right side of colon is usually defined as the portion including caecum, ascending 
colon, the hepatic flexure and transverse colon, while the left side is defined as the distal 
portion from the splenic flexure, i. e. descending colon, the sigmoid and rectum. In some 
studies the splenic flexure is included in the right colon.  
 
When comparing CRCs in different locations, right-sided lesions in general show more 
aggressive features than left-sided as reflected in morphology and stage. Poor 
differentiation, mucinous type, larger size, higher TNM-stage, vessel invasion and 
expanding tumor margin occur more frequently in right-sided lesions, while annular  
and polypoid growth and an infiltrating tumor margin are more common in left-sided 
lesions 
165
. Conversely, poorly differentiated and mucinous tumors are more frequently 
seen in the right colon 
166
. Right-sided colon cancers also show a higher frequency of 
node positive disease as well as a shorter median survival compared to left-sided (78 vs. 
89 months, p<0.001) 
167
.  In accordance to above, there is a gradual increase in the ratio of 
right to left colon cancer with age in female patients. In male patients, there is a greater 
proportion of left-sided cancers in middle-aged, while right-sided lesions predominate in 
young and old age groups 
165
. 
 
Since the 1980s there has been a persistent increase in the percentage of right-sided colon 
cancers with an associated decrease in the percentage of left-sided colon and rectal 
cancers 
167, 168
. The cause behind this is poorly understood and likely multifactorial. It 
may reflect the growing use of colonoscopy and screening, as well as a changing age and 
sex distribution of the disease since elderly patients and women tend to have more right-
sided tumors. Changing dietary habits (high fat and low fiber) has also been implied. The 
left-to-right shift of incidence is reported to be higher among women than men 
169
. 
 
CRC and family history 
 
The clinicopathological characteristics of LS, FAP and other CRC syndromes are well 
known. However, the morphological profile of the majority of familial CRC cases is 
unknown. Patients with a family history of CRC have been shown to be relatively 
younger and more likely to carry right-sided tumors. Also, sigmoidal and rectal cancers 
appear to be less frequent in patients with a positive family history of CRC compared to 
sporadic cases 
93, 170
. Few studies have addressed the histopathological profile of non-LS 
non-FAP familial CRCs, although there are comparisons of the morphology of tumors in 
LS and FCCTX. These reports have shown that cancers in FCCTX more often are located 
in the distal colon and rectum, more often show lymph node metastases and usually 
display conventional glandular morphology in contrast to the medullary or signet-ring cell 
features of LS tumors. Also, findings associated with LS such as poor differentiation, 
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mucin production, TILs, Crohn-like peritumoral lymphocytic reaction, lack of dirty 
necrosis and circumscribed tumor border, are less often found in FCCTX. In addition, 
patients with FCCTX have a lower risk of CRC, develop tumors at a later age, display 
more aneuploidy tumors and have less often extracolonic tumors in their families 
compared to patients with LS 
171, 172, 105
. Although these morphological and clinical 
finding support the existence of FCCTX as a separate entity from LS, little is known 
about the genetic alterations and mechanism of carcinogenesis behind this form of CRC.  
 
CRC and emergency presentation  
As discussed previously 15-30% of CRCs present themselves as emergency cases, most 
often due to obstruction (78%), perforation (10%) or bleeding (4%) 
40, 41
. The most 
common sites for tumor obstruction are the left colon and the sigmoid 
173, 174
 which is in 
line with the smaller luminal diameter and more solid fecal content in the left side of 
colon compared to the right. The risk for obstruction seems to be highest at the splenic 
flexure 
173, 174
. The most frequent sites for perforation are reported to be the sigmoid and 
caecum 
175
.  
Patients undergoing acute surgery are older than the elective ones (mean age 68.6 years 
compared to 66.3 years). Both young patients (<40 years) and old patients (>80 years) 
with CRC more often present as emergencies, probably because both groups are at risk of 
having their symptoms ignored. Some reports have shown a female predominance, but the 
role of estrogen in this setting is yet to be defined 
41, 176
. 
Many studies report poorer outcomes for patients who undergo emergency surgery, both 
during their initial hospital stay and their long-term survival 
40, 41, 176
. Acute and severe 
disturbances of body physiology may explain the differences in short-term perioperative 
survival.  Emergency CRCs have been associated with a higher risk of metastatic disease, 
possibly because of occult liver metastases already at the time of surgery, although not 
necessarily showing a higher rate of local recurrence 
173, 176
. In one study, the five year 
overall survival for emergency patients was 39.2% compared to 64.7% for elective cases 
41
 and a median survival time of 59 months compared to 82 months has been reported 
177
. 
Advanced tumor pathology and tumors with unfavorable histologic features may provide 
the basis for the differences in outcome. Emergency patients tend to have more advanced 
cancers (AJCC stage III and IV) and more T3 and T4 tumors as well as a higher rate of 
N1 and N2 cases, compared to elective patients. According to some studies, on a stage-
for-stage analysis, the survival rates remain worse for emergency cases, even after 
substratification for factors such as lymph node status and presence of extramural 
lymphovascular invasion 
41, 177
. Positive resections margins are also more frequent among 
cases presenting as surgical emergencies 
177
. 
Several studies have found no differences in the morphological profile of emergency and 
elective CRCs 
173, 178-180
. Extramural venous invasion, however, has been reported as 
being more common in emergency cases 
177
. In one study perforated tumors were found 
to present more often with distant metastases, although they were more seldom poorly 
differentiated and had less lymph node involvement than non-perforated cases 
181
.  The 
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findings are contradictory and difficult to interpret but might represent differences 
between emergency and elective cases in the molecular features that lie behind 
hematogenous and lymphatic spread. 
Summary  
As presented above, the histopathological profile of CRC seems to show considerable 
variation in relation to sex, age, tumor location, family history and mode of presentation, 
although the biological background for this is still largely unclear. These findings could 
however speak for different mechanisms of tumor development in men and women, 
young and old patients, proximal and distal colon, sporadic and familial cases and elective 
and emergency CRCs. Since many of the genes involved in CRC carcinogenesis are 
morphogenes, i. e. genes that have major influence on cell and tissue morphology, 
differences in tumor phenotype could reflect differences in the underlying genetic 
contribution.   
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6. AIMS OF THE THESIS____________________________ 
The overall premise of this work is the notion that tumor morphology could reflect the 
genetic contribution or underlying tumorigenic mechanisms. Although the underlying 
mechanism itself might not be elucidated, identifying histopathological differences 
between different groups of tumors will support the idea of different etiological 
backgrounds in these groups. 
The specific aim of each paper was: 
Paper I 
To determine whether 11 newly identified genetic susceptibility loci were associated with 
tumor morphology to confirm them as distinct and etiologically different risk factors in 
colorectal carcinogenesis. 
Paper II 
To provide a detailed and systematic histopathological characterization of CRC in a large 
population-based cohort, by comparing the morphology of tumors in men and women, in 
different age groups, in different anatomical locations, and in sporadic and familial cases, 
in order to isolate the effects of these four factors. 
Paper III 
To compare the clinicopathological profile of emergency and elective cases of CRC in 
relation to sex, age groups, location, and family history of CRC. 
Paper IV 
To use the family history of cancer in patients with CRC together with genotyping and 
tumor morphology in order to find support for and define new CRC syndromes.  
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7. MATERIALS AND METHODS____________________ 
Materials 
Patients 
All patients in studies I-IV where recruited within the Swedish Low-Risk Colorectal 
Cancer Study which was design to identify both new high-risk genes in families with 
strong inheritance for CRC as well as putative low-risk alleles in a population based 
material of CRC. This study, initiated by Professor Annika Lindblom, Karolinska 
Institutet, recruited patients consecutively operated for CRC during 2004 to 2006 from 14 
different surgical clinics in Mid-Sweden (the regions of Stockholm and Uppsala). Of 
4585 patients operated during this time period, 2175 (47.7%) were included in the study. 
The corresponding figures for Stockholm County were 2573 and 1205 (46.8%). Patients 
who were too old or too ill to be invited were excluded; otherwise all patients were 
eligible. Of the 2410 patients that were not included, 639 died before they could be asked 
to participate or before blood could be drawn. The rest declined to participate, withdrew 
their consent or were excluded for various reasons.   
 
For the comparison of emergency and elective cases (paper III) only patients from 
Stockholm County were selected. The reason for this was that the medical records from 
which we gathered information about the type of operation were easily available to us. 
For further details see the Materials and Methods section in each paper I-IV. 
  
Histological specimens 
For all patients in studies I-IV an attempt was made to obtain the original H&E-stained 
slides of tumor(s) from the pathology department involved, as well as the original 
pathology report. When slides could not be found in archives new sections were prepared 
from paraffin blocks if possible. In 0.4% of cases only biopsy material was available and 
in 2.0% the specimen consisted of a polypectomy or local resection. In the rest of the 
cases assessment was made on the surgical specimen. 
 
Although all patients examined in studies I-IV originated from the same cohort the exact 
number of reviewed cases stated in each paper varies slightly. In paper I, the number of 
included cases (n=1572) refers to the number of patients were a surgical specimen could 
be re-reviewed, where blood could be drawn, where the family history was known and 
where cases of FAP and LS were excluded. In paper II, the number of included cases 
(n=1613) refers to all patients with a surgical specimen available. In the analysis of 
morphology in relation to family history those with unknown family history and cases of 
FAP or LS were of course omitted. In study IV patients were consecutively included with 
an arbitrary cut-off at 1720 patients (rendering 1612 available specimens), mainly to 
allow for the histological assessment to be finished in time. 
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Methods 
Histopathological assessment 
All tumors included in study I-IV were re-reviewed in the same way according to a 
standardized protocol. Tumor location and information about multiple synchronous 
tumors was gathered from the original pathology report as well as the Regional Oncologic 
Center registry. Information on whether the patient had received pre-operative chemo- 
and/or radiotherapy (for rectal cancers) was obtained from the clinical history on the 
pathology referral sheet and from lists provided by the Regional Oncologic Centers.  
 
The micromorphological parameters assessed were tumor grade, stage, medullary 
features, mucin production, mucin type, Crohn-like peritumoral lymphocytic reaction, 
tumor infiltrating lymphocytes (TILs), desmoplasia, tumor necrosis, vascular invasion, 
perineural growth, co-existing polyps, budding and type of tumor margin. For the exact 
definition of these features and how they were assessed see the Materials & Methods 
section in paper I or II.  
 
Genotyping 
All cases in study I were genotyped for one SNP from each CRC risk locus: rs16892766 
on 8q23.3, rs6983267 on 8q24.21, rs719725 on 9p24, rs10795668 on 10p14, rs3802842 
on 11q23.1, rs4444235 on 14q22.2, rs4779584 on 15q13.3, rs9929218 on 16q22.1, 
rs4939827 on 18q21.1, rs10411210 on 19q13.1, and rs961253 on 20p12.3. In study IV the 
cases were genotyped for only rs6983267. Six of the SNPs (rs719725, rs4444235, 
rs4779584, rs9929218, rs10411210, and rs961253) were typed using TaqMan SNP 
genotyping assay (Applied Biosystems, Foster City, CA). Genotyping of the remaining 
five SNPs (rs6983267, rs16892766, rs10795668, rs4939827, and rs3802842) were 
performed using a technology developed by Nanogen, at deCode Genetics, Reykjavik, 
Iceland. 
 
Statistical analyses 
In study I the cross tabulation between SNP data and morphology was done and Pearson 
χ2 test was used for calculating the p-value. The significant results from these genotype–
phenotype analyses were studied further by using the DeFinetti program 
(http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl). Deviations of genotype 
frequencies in cases and controls from those expected under Hardy-Weinberg equilibrium 
were calculated by χ2 tests (one degree of freedom). Odds ratios, 95% confidence 
intervals, and the corresponding p values were calculated using the same program. Results 
are presented without correction for multiple testing to avoid the loss of valuable 
information due to the limited number of patients. 
In studies II and III determination of the association between clinicopathological features 
and sex, age group, location, family history (and type of operation in study III) was 
performed by univariate and multiple binary and multinomial logistic regression analysis 
for categorical outcomes and linear regression analysis for continuous outcomes. Results 
   43 
are presented as odds ratios (ORs) from the logistic regression and as regression 
coefficients (b) from the linear regression. In addition, factor analysis (extracting factors 
using principal components analysis) with variance maximizing (varimax) rotation was 
performed to form a concise description for all the variables included in the study.  
 
In study IV Mann-Whitney U-test, Students T-test and Speaerman´s rank-order analysis 
were used. Correlation between syndromes and morphology was investigated using cross 
tabulation-analysis and Pearson χ2 test.  
 
The significance level for all statistical tests was set at 0.05 but also non-significant p-
values were recorded. 
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8. RESULTS__________________________________________ 
Paper I 
Of the 11 tested loci (SNPs) six showed statistically significant correlations to 
morphological parameters and a total of 10 genotype-phenotype associations were 
significant.  After the DeFinetti analysis (to obtain the ORs and confidence intervals) five 
SNPs remained significantly associated with morphological parameters (see Table 1 in 
paper I). 
 
Heterozygous carriers of the T allele of rs6983267 (8q24.21) had decreased Crohn-like 
peritumoral lymphocytic reaction (p=0.021). For rs10795668 (10p14), the heterozygote 
genotype was associated with poor differentiation (p=0.015). Homozygosity for the C 
allele of rs4444235 (14q22.2) was related to decreased Crohn-like peritumoral reaction 
(p=0.024). The T allele of rs10411210 (19q13.11) was negatively associated with 
desmoplastic response (p=0.004 for homozygotes). For rs961253 (20p12.3), the variant A 
allele was associated with mucin producing tumors (p=0.010 and 0.009 for homozygotes 
and heterozygotes respectively). Homozygous carriers of the A allele more frequently had 
tumors with circumscribed margins (less often infiltrative, p=0.034) but for heterozygous 
carriers an opposite effect was suggested. 
Paper II 
The univariate comparison between men and women (Table 1 in paper II) showed that 
female patients significantly more often had tumors with TILs >30/10 high-power fields 
(HPF) and tumors of medullary type. Women also showed a lower frequency of tumors 
with an infiltrative margin. In the multivariate analysis (Table 2 in paper II) a significant 
difference remained only in TILs (p=0.002). 
 
The univariate comparison between the three age groups (Table 3 in paper II) showed that 
patients aged <60 years had a significantly lower frequency of multiple tumors, mucin 
production (0–50% mucin), and TILs >30/10 HPF compared to the reference group (>75 
years). They, however, showed a higher frequency of AJCC stage III tumors, N1 and 
N2/N3 tumors, vascular and perineural invasion, and infiltrative tumor margin. In the 
multivariate analysis (Tables 2 and 4 in paper I) significant differences remained for 
multiple tumors, AJCC stage III, N2/N3, perineural invasion and infiltrative tumor 
margin, which had the highest level of significance (p<0.0001). In addition, AJCC stage 
II and IV tumors and T4 tumors were significantly more common in the youngest age 
group. 
 
In the univariate comparison (Table 5 in paper II) most of the histological features studied 
showed a significant difference between the left colon and rectum compared to the right 
colon (reference group). The most significant differences between the left and right colon 
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were seen in mean tumor diameter, T3 tumors, proportion of poorly differentiated tumors, 
mucin production, mucinous type (>50% mucin), TILs and medullary type. All of the 
differences from the univariate analyses, except for the higher frequency of N2/N3 tumors 
in the left colon, remained significant in the multivariate analyses, where the highest level 
of significance (p<0.0001) was seen for tumor diameter, proportion of poorly 
differentiated tumors, Crohn-like reaction, TILs, medullary type, T3 tumors, and 
mucinous type. In the univariate comparison between rectum and right colon, most of the 
features listed in Table 5 in paper II showed highly significant (<0.0001) differences and 
all of these remained significant in the multivariate comparison. 
 
The only difference between the sporadic and the familial group was seen in vascular 
invasion, which was more common among the familial cases (p=0.012 in the multivariate 
analysis, Table 2 in paper II). 
 
All the dependent and independent variables could be grouped into six different factors 
(components) according to Table 7 in paper II. 
Paper III 
The univariate comparison between elective and emergency cases (Table 1 in paper III) 
showed that the emergency cases had significantly more often multiple tumors, vascular 
invasion, perineural invasion and infiltrative tumor margin. There was no difference in 
mucin production, but the tumors in the emergency group more often showed a signet-
ring cell component. Also, the emergency patients had more AJCC stage II-IV tumors 
than stage I tumors, compared to the elective group. They also had higher T- and N-stage, 
but more seldom TILs>30/10 HPF. In the multivariate comparison  (Table 2a and b in 
paper III) together with sex, age group, location and family history, type of surgery 
remained a significant factor for multiple tumors, vascular invasion, perineural invasion, 
tumor margin, mucin type (signet ring cell component vs. only extracellular), AJCC-
stage, T- and N-stage and TILs. The highest level of significance (p<0.0001) was seen for 
multiple tumors, perineural invasion, infiltrative tumor margin, AJCC stage III vs. I and 
N1 and N2/3 vs. N0. 
 
In both univariate and multivariate analysis of the effect of sex, age group, location and 
family history on the type of surgery, the only significant result was seen for location 
where there was a much lower risk of having to undergo emergency surgery for a rectal 
cancer compared to a right sided colon cancer (p<0.0001 in the multivariate analysis).  
 
All the dependent and independent variables could be grouped into seven different factors 
(components) according to Table 3 in paper III. 
Paper IV 
When comparing the number of cancers between the families of the sporadic and familial 
CRC cases (Table 1 in paper IV), there were significantly more cancers of all types in the 
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family history of the familial cases of CRC (p<0.001) and also significant more bladder 
cancer (p<0.001), prostate cancer (p<0.01), melanoma (p=0.01), gastric cancer (p<0.01).  
 
Testing the SNP rs6983267, already known to be associated with both CRC and prostate 
cancer, confirmed this SNP to be more common in families with both colorectal and 
prostate cancer (p=0.017).  
 
An analysis of the CRC morphology in the index case in relation to the different 
suggested syndromes gave some support for different morphological profiles in four of 
the five tested syndromes (Table 2 in paper IV). The CRCs in the cancer families 
(families with at least two CRCs and three or more other types of cancer, in first- or 
second-degree relatives or cousins) displayed more often vascular invasion. The tumors in 
the CRC and prostate cancer families were associated with budding and these patients 
also more frequently had lymph node metastases. The cases from CRC and gastric cancer 
families more often had tumors with Crohn-like peritumoral lymphocytic reaction. 
Finally, CRC cases in families with CRC and melanoma showed association to poor 
differentiation. 
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9. DISCUSSION____________________________________ 
Paper I 
In this study we have demonstrated a unique pattern of morphological parameters 
associated with five recently published low-risk gene variants of CRC located on 
chromosomes 8, 10, 14, 19 and 20. The susceptibility region on 8q24.21 (rs6983267) has 
previously been associated with an elevated risk of adenoma development as well 
increased risk of prostate cancer 
111, 115
. Also, this SNP has been related to family history, 
MMR status, tumor site and tumor stage 
182
. In our study, heterozygosity for the variant 
allele (T) in this locus was demonstrated to be negatively associated with Crohn-like 
peritumoral lymphocytic infiltration, a host immune response that has been linked to 
improved patient survival in some studies 
125, 126
. Therefore, a five-year follow up of our 
patients would be interesting and could perhaps reveal if variations in this SNP are related 
to outcome. 
For rs719725 (9p24) the results for desmoplastic reaction, budding, and necrosis were 
inconsistent in homo- and heterozygous carriers; heterozygotes for the variant allele (C) 
seemingly having an increased risk and homozygotes a decreased risk. Although showing 
significant p-values, we therefore regarded these results as false positive and unlikely to 
be associated with any of the studied phenotypes. Homozygosity for variant allele (T) of 
SNP rs10411210 on 19q13.11 was negatively associated with desmoplastic reaction. This 
feature is generally considered favorable 
130
, although there are conflicting reports 
regarding the role of fibrotic stromal response in cancer development and whether it 
favors the host or the tumor
 131
. Also in this case, a five-year follow up of our material 
could be of interest. The region on 20p12.3 harbors a risk allele (A) associated with 
mucin-producing tumors. Mucinous tumors have been showed to confer a poorer 5-year 
survival compared to non-mucinous CRCs 
145
. Many mucinous carcinomas are however 
MSI-H positive and thereby low-grade and carrying a better prognosis
 148
. In addition, 
homozygous carriers of the A allele showed an association to tumors with circumscribed 
margin. However, for heterozygous carriers the results suggested an opposite effect 
making interpretation of this finding difficult. 
Heterozygosity for the variant allele (A) at the 10p14 locus, reported to have a protective 
effect against CRC, was associated with poorly differentiated tumors but with no other 
MSI-like morphology. Similar to the locus on 8q24.21, the 14q22.2 locus harbors an 
allele negatively correlated to Crohn-like peritumoral lymphocytic reaction. However, for 
the variant on 8q24.21, it is the allele providing a protective effect (T) that is associated 
with this tumor phenotype, while for the variant on 14.q22.2, it is the risk allele (C). 
The studied SNPs have pointed out regions associated with morphological features, but it 
is difficult to interpret some of these correlations in their biological context as the exact 
pathogenic variation is still not known for all risk loci. However, the 8q24.21 locus has 
been demonstrated to affect the last nucleotide of a binding site for TCF4, thereby up-
regulating the oncogene MYC, which might explain some of the increased risk of CRC for 
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carriers of the risk allele (G) 
116
. The closest gene to 20p12.3 is BMP2, and similarly, 
BMP4 maps close to the 14q22.2 locus 
183
. Both these genes belong to the TGFβ-family, 
which is a morphogenic factor involved in CRC carcinogenesis as discussed in Chapter 2. 
For the locus 10p14, there is no coding transcript or predicted gene within 0.4 Mb of 
sequence from the SNP 
122
. The 19q13.1 locus maps to a 96-kb block of linkage 
disequilibrium that contains the gene RHPN2, suggested to be involved in in the biology 
of invasiveness of CRC 
184
. 
In a study such as this where many tests have been performed the problem of multiple 
comparisons must of course be addressed, although the usual Bonferroni correction might 
be too strict. Since it is not clear what the appropriate correction needs to be and since this 
is the first study of detailed morphology associated to CRC low-risk alleles, we thought it 
was important to show all possible results for future comparisons.  
In the study of cancer as a complex disease, it is expected that numerous genes and 
pathways will act together and that this will influence risk effects. The effect of each 
individual genetic variant above has been demonstrated to be extremely small with 
relative risks only just above 1. Hence, understanding the genetic effects on function as 
seen by clinical parameters such as tumor phenotype is important. That cancer-causing 
genes do influence morphology has been shown from the study of high-risk genes 
185
. 
With regard to this, it would be interesting to add immunohistochemical profiling to our 
study and relate the outcome of this to the various SNPs studied here. This 
immunohistochemical panel could for example include expression of proteins coded for 
by genes located close the SNPs described above (MYC, BMP2 and 4, and RHPN2), but 
also other proteins important in CRC tumorigenesis such as KRAS, BRAF, SMAD2, 4 
and 7, β-catenin, p53, TGFβ-receptors and MMR-proteins. Molecules involved in cell 
adhesion, invasiveness and metastatic potential such as E-cadherin, CEA, MMPs, VEGF 
and PD-ECGF could also be included in the marker panel, together with cytokeratins, 
CDX2 and mucin stains.  
In summary, the knowledge of genes or genetic variants involved in cancer development 
has future clinical potential in prevention, diagnosis, and prognosis and even for decisions 
regarding therapeutic strategies. However, our results are preliminary, and more studies 
are required to confirm these findings. In particular, a long-term follow-up would be 
important to evaluate the survival implications related to the investigated risk alleles.  
 
Paper II 
Sex 
Tumors with TILs>30/10 HPF, medullary features and circumscribed margin were more 
common in women than in men, although in the multivariate analysis only the difference 
in TILs remained significant (OR 1.482, p=0.002). A high number of TILs, medullary 
features and circumscribed tumor margin are all features associated with MSI-H tumors. 
The results support previous studies that have shown cancers with MSI-H phenotype to be 
more common in women than in men 
80, 81
.  Differences in hormonal status could be a 
possible explanation. There is clinical evidence that estrogen protects against the 
   49 
development of CRC, but its exact role in the carcinogenesis is not well understood. 
Exogenous estrogen has been associated with the prevention of hypermethylation-
associated loss of estrogen receptors, which can lead to unregulated growth of the colonic 
mucosa 
186. At least three different estrogen receptors, ERβ1 (estrogen receptor β1), ERβ2 
and ERβ5 have been detected in normal and malignant colorectal epithelium. Studies 
have shown that ERβ1 and ERβ2 expression is lost in many CRCs. High ERβ1 expression 
is associated with low-grade carcinomas, lower T-stage, mucinous phenotype and MSI. 
High ERβ2 expression is found in carcinomas with right-sided location and those with 
lymph node metastases. Loss of ERβ1 is thereby associated with more aggressive CRCs, 
whereas the opposite is true for ERβ2. It has been proposed that ERβ1 activation 
predisposes to MSI and that such activation is somehow suppressed by estrogen before 
the menopause. Estrogen withdrawal will lead to a rebound increase in ERβ1 expression 
and thereby a higher risk of MSI-H carcinomas in older women 
187
. This is in line with 
older women having more MSI-H cancers compared to younger women, in contrast to 
men, where the frequency of MSI cancers decreases with age 
160, 188
. 
 
Age 
When comparing CRCs in different age groups we chose cut-off points at 60 and 75 years 
in order to get three groups of comparable size. Multiple synchronous tumors were clearly 
much less common (OR 0.204, p<0.003 in the multivariate analysis) in the youngest 
group (<60 years) compared to the reference group (>75 years). The results suggest that 
age is a crucial factor for this feature. This may be due to young patients having a better 
anti-tumorigenic immune response, which prevents them from developing multiple 
cancers. Also, they may not yet have accumulated as many mutations in their colonic 
mucosa as older patients. Alternatively, the tumors of the young patients may be more 
fast-growing so that they will cause symptoms and be diagnosed before additional tumors 
have developed. Interestingly, patients aged less than 60 years showed more locally 
advanced tumors with more vascular and perineural invasion and infiltrative tumor 
margin. They also showed higher ORs for AJCC stage II–III, T4 and N2/N3 tumors, than 
the reference group. The results indicate that younger patients have a more aggressive 
disease, which is in line with some previous reports 
163, 165
, but in contrast to others 
164
.  
When looking at the univariate analysis, the tumors of the young patients displayed less 
mucin production, less Crohn-like lymphoid reaction, more seldom medullary features, 
and had a lower frequency of TILs. These features constitute the opposite of the MSI 
phenotype seen in older patients 
80
. The finding of less mucin production is in contrast to 
reports showing mucinous tumors to be more frequent in young patients 
164
. None of these 
features, however, remained significant in the multivariate analysis. All in all, the 
patient’s age seems to be correlated to tumor aggressiveness, rather than to morphology. 
The tumors of the young patients were more systemically advanced by the time of 
operation, thus indicating faster growth. 
 
Location 
Multiple tumors were much less common in the rectum than in the right colon (OR 0.308, 
p<0.0001 in the multivariate analysis). This is probably for anatomical reasons: the short 
length of the rectum and the narrow lumen result in symptoms and early discovery before 
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any possible additional tumor could develop. The same anatomical factors probably 
explain why the tumors in the left colon and rectum were smaller than the tumors in the 
right colon. In addition to the larger lumen of the right colon, its bowel contents are also 
looser, which makes tumors in this location escape early detection by not causing 
symptoms such as obstipation. The tumors in the rectum, and to a certain extent in the left 
colon, tended to be of lower AJCC- and T-stage than those in the right colon. This 
characteristic might also be explained by the fact that these tumors are detected earlier.  
Mucinous tumors were more common in the right colon compared to both the left colon 
and the rectum. Because mucin production is part of the morphological spectrum of MSI-
H tumors, which are more common on the right side, this is not surprising. The same was 
true for tumors with a high number of TILs and medullary features, which are also 
characteristics of MSI cancers. The frequency of signet-ring cell morphology parallels 
that of mucin production as a whole, with tumors showing this feature being significantly 
more common in the right colon. As discussed in Chapter 4, signet-ring cell carcinomas 
are known to present themselves at a higher stage, confer a poorer prognosis and show a 
different pattern of genetic changes compared to conventional adenocarcinomas. Rectal 
tumors showed more perineural invasion, and an infiltrative tumor margin was more 
frequent in both rectal and left-sided cancers, compared with findings in right-sided 
cancers. Again, anatomical factors may lie behind this difference, as the rectum, which 
mainly consists of an outer longitudinal muscle without haustrae and with its own 
mesentery, is innervated by a surrounding plexus of sympathetic and parasympathetic 
fibers. This, in turn, results in a high concentration of nerves close to the wall of the 
rectum. The limited space for luminal expansion in the rectum and left colon – because of 
the smaller diameter – may also force tumors in these locations to grow outward, hence 
causing a more infiltrative pattern. For most morphological parameters the differences 
seem to be greatest between right-sided colon cancers and rectal cancers. In addition, 
most features show a gradient from right colon to left colon to rectum, as indicated by the 
ORs. 
Most of the morphological parameters studied seem to be related to tumor location rather 
than to age-group according to the multivariate analysis. This is interesting since there are 
several embryological, environmental and genetic differences between different parts of 
the large bowel. Proximal colon originates embryologically from the midgut, while distal 
colon and rectum originate from the hindgut. Histologically the epithelial cells of 
proximal colon contain dense mucous apical vesicles, while the proportion of goblet cells 
is highest in distal colon. Rectum on the other hand shows a high concentration of 
endocrine cells. The bacterial fermentation products in proximal colon are rich in short-
chain fatty acids and ethanol, while products of protein fermentation dominate distally. 
Proximal cancers are more related the MSI pathway and the CpG methylator phenotype, 
while in distal cancers the CIN pathway with mutations in KRAS, APC, TP53 and 
DCC/SMAD4 is predominant. Rectal cancers are rarely MSI-H positive, whereas the 
incidence of CIN is high. However, compared with colon cancers, rectal cancers show a 
significantly higher number of mutations. Higher expression of nuclear β-catenin, p53 and 
COX2 is also seen in rectal cancers compared to colon cancers 
189
.  
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Sporadic vs. familial 
There were remarkably few differences in the morphology between sporadic and familial 
CRCs. Familial CRCs, however, showed a higher frequency of vascular invasion (OR 
1.438, p=0.012 in the multivariate analysis). 27.4% of the familial cases displayed this 
feature, compared to 21.1% of sporadic cases. Considering the retrospective nature and 
the size of the study, as well as cost-, time-, and labor-related aspects because of 
additional immunohistochemistry, we chose not to differentiate between venous and 
lymphatic invasion. Given the problem with low reproducibility, high interobserver 
variability and high false negative rates as discussed in Chapter 4, our rate of vascular 
invasion, which is in the lower range of previously reported frequencies of 10 to 89.5% 
137
 
might represent an underdiagnosis of this feature.  
 
The finding of a higher frequency of vascular invasion in familial tumors however raises 
the question of whether tumors in the familial group have different biological properties, 
such as specific tumor antigens or adhesion molecules that influence the ability to invade 
vessel walls. Protein markers such as apoptosis protease activating factor-1 (APAF-1), 
mammalian sterile 20-like kinase (MST1), urokinase plasminogen activator receptor 
(uPAR), Raf-1 kinase inhibitor protein (RKIP) and VEGF have been associated with 
vascular invasion 
190
. The urokinase plasminogen activator (uPA)/uPAR system is 
associated with the degradation and regeneration of the basement membrane and 
extracellular matrix and uPAR itself is involved in cell movement and adhesion. RKIP has 
recently been characterized as a metastasis suppressor gene and loss of it has been 
associated with an increased frequency of distant metastases in CRC 
190
.  All in all, our 
finding may speak for a difference between sporadic and familial CRCs in the expression 
of proteins facilitating vascular invasion, but extensive immunohistochemical 
comparison, including some of the above mentioned markers, of the two groups is 
required. One could expect that differences in vascular invasion between the two groups 
would be reflected in N stage. However, no such difference was evident. A higher 
frequency of vascular invasion should feasibly lead to more distant metastases, but M 
stage was not possible to assess in our material. A follow up of our patients after 5–10 
years could perhaps reveal a correlation between vascular invasion and survival time, as 
has been shown in previous reports 
190, 191
. 
 
Factor analysis 
We found that AJCC- and N-stage were in the same component (factor 1) together with 
vascular invasion, perineural invasion, budding, and tumor margin. This is not surprising 
because these are all features related to the extent of tumor spread and tumor 
aggressiveness. T-stage had a meaningful loading on two components and was therefore 
ignored in the interpretation. Mucin and mucin production were grouped in the same 
component (factor 2). Crohn-like peritumoral lymphocytic infiltrate is part of the MSI 
spectrum, but in our analysis it was not grouped in the same component (factor 3) as the 
other MSI variables grade of differentiation (negative correlation to well/moderate), TILs, 
and medullary type. This finding supports the fact that peritumoral lymphocytic 
infiltration is a different entity from TILs and that it may have a different biological 
implication. Desmoplastic reaction and Crohn-like peritumoral lymphocytic infiltration 
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were grouped together with tumor diameter (factor 4). The fifth component (factor 5) 
consisted of age group and multiple tumors. This is in keeping with the multivariate 
analysis which showed that patients younger than 60 years had significantly fewer 
multiple tumors than the reference group. In addition, our factor analysis showed a sixth 
component (factor 6), consisting of sex and family history. (Please note the error 
regarding this in the Factor analysis section under Discussion in paper II). Location had a 
meaningful loading on both factors 4 and 5 and was therefore ignored; however, this 
loading was not so high, -0.41 and -0.44, respectively. 
 
In summary, we have in this large and systematic study shown that tumor location is the 
factor having most influence on morphology. The results are in line with tumors in 
different locations having different genetic and embryological backgrounds as well as 
developing in different physiological settings. Age is the most important determinant for 
the presence of multiple tumors and an important factor for the aggressiveness of the 
disease. The results could speak for different mechanisms of tumor development in young 
and old patients. Few morphological features are related to sex and almost none to family 
history. The observed morphological differences in our material could perhaps be 
supported by immunohistochemical markers as outlined in the discussion about paper I, in 
a subset of the patients. The prognostic significance of our findings must, however, await 
a 5 to 10 year follow-up. 
Paper III 
According to our study emergency cases of CRC more often show multiple tumors (OR 
3.154, p<0.0001 in the multivariate analysis). This seems reasonable since multiple 
tumors should increase the risk for obstruction.  Emergency tumors tend to be of higher 
AJCC-stage (II-IV), T-stage (T4) and N-stage (N1-2/3), which is in line with previous 
reports 
41, 177
 and not surprising since T-stage and AJCC-stage reflects how locally 
advanced the tumor is. It seems reasonable that locally advanced tumors by growing 
through the bowel wall could be more prone to perforation. A locally advanced cancer 
would also be more likely to display vascular and perineural invasion, which is in fact 
shown in our material (OR 2.086, p=0.001 and OR 2.500, p<0.0001 respectively in the 
multivariate comparison). Vascular invasion in turn, would increase the probability of 
lymph node metastases as indicated by the N-stage.  
Interestingly, there was no difference in tumor diameter between the emergency and 
elective group. Nor was there any difference in the frequency of mucinous tumors or 
tumors showing necrosis. One would expect large, mucinous or necrotic tumors to more 
easily cause obstruction or perforation resulting in emergency surgery. However, the 
perforations associated with colonic cancer are mainly due to a direct mechanism of local 
destruction at the site of the cancer which does not necessarily mean that the tumor itself 
has to reach a certain size to achieve that. Also, in about one third of the perforated cases 
the perforation is located proximal to the cancer 
192
. In this situation, which is well-known 
by colorectal surgeons, a diastatic widening occurs in the cecum eventually creating a 
perforation. This is often the case in left-sided (sigmoidal) tumors. Due to the consistency 
of the stools in this region these cancers are prone to cause an obstruction which in turn 
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will widen the proximal part. The law of La Place states that the site of largest diameter 
requires the least pressure to distend. Hence, cecum is the most vulnerable part and will 
perforate at a certain diameter, described as 13 cm in the literature 
193
, due to a distal 
cancer in the left colon. Rectal cancers seldom present as emergencies (5.9%) compared 
to colon cancers (21.7%) 
41
, which is in line with rectal tumors causing early symptoms 
and being detected before they become advanced enough to cause obstruction. 
 
The emergency group showed more frequently mucinous tumors with signet-ring cells 
(OR 3.136, p=0.001 in the multivariate analysis). This type of mucin production with 
mucus pools filled with cells displaying a large cytoplasmatic mucin vacuole could make 
the tumor less cohesive and more soft and thereby more prone to perforation. We found 
tumors with TILs>30/HPF to be less frequent in the emergency cases compared to the 
elective ones.  As discussed previously, TILs is a distinct feature of MSI-H tumors. About 
30% of right-sided CRCs are shown to be of MSI-H type and the majority of MSI-H 
tumors are located on the right side 
194
. The most common site of obstruction has been 
reported to be the sigmoid 
174
 which might explain the underrepresentation of tumors with 
high number of TILs among the emergency cases. Irrespective of the MSI status, the 
invasion of lymphocytes could reflect antitumor immunity 
128
 and in emergency cases 
leading to perforation this cellular reaction might not be developed. Three MSI-associated 
features, multiple tumors, signet-ring cell carcinomas and Crohn-like lymphocytic 
reaction, were more common among the emergency cases while a high number of TILs 
and circumscribed tumor margin was more frequent among the elective cases. No 
difference was seen in poor differentiation, mucin production or medullary tumors which 
are also included in the MSI spectrum. Thus, in sum MSI-H features of CRC did not 
appear to predominate in either the emergency or elective group. 
 
Vascular invasion, as mentioned above, was more common among the emergency cases 
in our material. This is in line one previous report which showed extramural venous 
invasion to be more frequent in this group 
177
. It seems likely that emergency tumors 
being more locally advanced will show a higher frequency of both vascular and perineural 
invasion. This is probably also reflected in those reports showing a worse prognosis for 
emergency cases 
40, 41, 176
. The emergency cases also displayed a higher frequency of 
tumors with infiltrative margins (OR 2.452, p<0.0001 in the multivariate comparison), 
which is in accordance with the fact that locally aggressive tumors could cause 
perforation. When looking at the effect of sex, age group, location and family history on 
type of surgical presentation, only location turned out to be a significant factor with a 
clearly lower risk of having to undergo emergency surgery for a rectal cancer compared to 
a right sided cancer. This finding is not surprising and is in line with the clinical 
appearance of rectal cancer and its surgical management. 
 
In the factor analysis AJCC- and N-stage were in the same component (factor 1) together 
with vascular invasion, perineural invasion and tumor margin. As discussed in paper II 
these are all features related to extent of tumor spread and tumor aggressiveness. Mucin 
production and mucin type were grouped into the same component (factor 2). Grade of 
differentiation (negative correlation to well/moderate), number of TILs and medullary 
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type are all features related to the MSI-H phenotype of CRC (factor 3). Crohn-like 
peritumoral lymphocytic infiltrate, which is also an MSI-feature, was however not 
included in this factor. Tumor diameter and desmoplasia were grouped together (factor 4). 
Factor 5 included location and peritumoral lymphocytic infiltration. This is in accordance 
with our previous observation in paper II that the frequency of peritumoral lymphocytic 
reaction is higher in right-sided CRCs. Family history and multiple tumors were grouped 
together (factor 6) and budding separately (factor 7).  
 
All in all, emergency CRCs in general show a more aggressive histopathological profile 
and more advanced stage, than elective CRCs. Since the distribution of emergency and 
elective cases was essentially similar between right and left colon the observed 
differences cannot primarily be attributed to differences in macroenvironment or location 
between the two groups. This raises the question whether CRCs presenting as 
emergencies may have a different etiological or genetic background. The well-known fact 
that emergency colorectal surgery is associated with a worse outcome, including higher 
morbidity and relapse, has traditionally been characterized mainly as a technical and 
surgical problem. Discussion about surgery in an emergency situation under conditions 
less optimal and sometimes by a surgeon who is not necessarily specialized in colorectal 
surgery, has dominated the debate. This has led to a more frequent use of adjuvant 
chemotherapy in the postoperative care.  Our study suggests that the complexity of the 
issue probably involves a more aggressive biology of the tumor itself. If future studies 
could classify the genetic background of these tumors a more precise and adequate 
oncologic treatment might be offered. Using SNPs to pinpoint chromosomal loci 
associated with an emergency phenotype and looking at genes located in or close to these 
loci could provide an insight into which pathways are involved in emergency contra 
elective cases. As suggested in paper I and II, immunohistochemical studies especially 
focused on markers for invasion, loss of cell adhesion, metastasis and proliferation rate 
(Ki67), could also help to further explore the eventual differences between the two 
groups. Furthermore, in our study we have not separated obstructive and perforated 
lesions. It seems reasonable that the two types of emergency tumors might show 
differences in morphology and/or immunohistochemical profile which could be addressed 
in a future study.  
 
Paper IV 
Known cancer syndromes often involve an increased risk for a whole spectrum of tumors, 
such as CRC, endometrial, gastric, renal pelvis and ileal tumors in LS and breast cancer, 
leukemia, sarcoma, and brain tumors in Li-Fraumeni syndrome. Also for the BRCA 
genes, the VHL, the APC and in fact almost all known cancer genes, a typical spectrum of 
different cancers is associated with each gene involved in the syndrome.  
When CRC cluster in families where none of the known syndromes are prevalent also 
other tumors are frequently seen. To find out if this was significant, we used a cohort of 
consecutive CRC cases and their family history of cancer among close relatives for the 
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study. After comparison of the family history it was clear that several tumors were more 
prevalent in the families with more than one CRC case. It is difficult to determine whether 
there was only one cancer family syndrome, with a differently increased risk for most 
cancers, or several – including a number of different tumor spectra. We tested each tumor 
type separately and found positive values for urine bladder, prostate and gastric cancer 
and melanoma. It is possible that only one cancer syndrome is responsible for the results 
and that some tumors show a positive correlation because they are common enough to 
give power on their own. However, urine bladder carcinoma is quite rare and still gives a 
positive correlation – while breast cancer, which is very common, does not seem to be 
more frequent in the familial group. Thus, there is likely at least some kind of specificity 
for one or several CRC syndromes but without the knowledge of underlying genetic 
contribution it is impossible to say which tumors are associated with which syndrome. 
 
One limitation of our study is that many of the diagnoses among family members were 
not verified from medical records. However, all abdominal malignancies with unclear 
diagnosis were verified in order to confirm or exclude CRC. Other diagnoses were coded 
as reported from the index patient if stated in detail and claiming good knowledge. Weak 
remembrance or uncertainty did not result in coding of a cancer diagnosis. Some 
malignancies were considered more uncertain than others. So, i.e. gynecological 
malignancies and hematological malignancies are often stated as such and only rarely 
specified in detail why we chose to use these terms for all cases reported regardless of 
how specific the diagnoses were expressed. 
 
The MSI status was not known to us, why we could not predict LS in a better way than by 
using the Amsterdam II criteria. Only about 1.2% of the patients in Sweden should have 
LS judging from a previous study 
93
. Such a small proportion is not likely to have 
influenced our results. Considering the results and the suggested syndromic tumors, only 
gastric cancer is associated with LS. Urinary bladder cancer has not been considered 
associated with LS, where cancer in the renal pelvis is seen, although rarely at all in 
Swedish families. Melanoma has not been reported to be overrepresented in LS. Quite 
recently a Norwegian study reported prostate cancer to be more common in LS-gene 
carriers than among the general population 
195
. Gastric cancer and gynecological cancer 
constitute typical tumors of the LS. However, in Sweden gastric cancer is rarely seen in 
LS families and endometrial cancer is often associated with CRC in non-LS families, why 
none is typical for LS in our experience (Annika Lindblom. Unpublished). 
 
An effort was made to find more evidence in support of the new syndromes suggested.  
Two different approaches, molecular genetic studies and studies of tumor morphology 
were used. Since the family history studies included all diagnoses on both the maternal 
and paternal side, both monogenic syndromes and complex inheritance – or both – could 
explain our findings. The monogenic syndromes will be tested for in future linkage 
analysis in families suggested to have monogenic disease as outlined in this study.  
However, we could immediately test the hypothesis of complex disease by choosing the 
SNP rs6983267 published to be associated with an increased risk of both prostate cancer 
and CRC, as discussed previously. We found support for this SNP to be associated with 
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an increased risk in families with both CRC and prostate cancer (p=0.017) which 
demonstrates a molecular evidence for at least one of the syndromes suggested. 
 
CRC predisposing genes are typically morphogenes and thus CRC tumors will 
demonstrate different morphology depending on the underlying genetic contribution 
185
. 
Tumor morphology and location of the tumors in the index cases were used for testing the 
hypothesis that tumors in the different syndromes might show different and typical 
phenotypic characteristics to support different underlying genetic etiology. We found 
statistically significant associations for four of five tested hypothetical syndromes; cancer 
families, CRC-prostate cancer families, CRC-gastric cancer families and CRC-melanoma 
families. The findings included only one of 15 tested tumor characteristics each, why this 
is not strong evidence for any of the syndromes. However, it still gives some support for a 
different genetic underlying cause of those syndromes.   
 
In conclusion, we used the family history of cancer in relatives of consecutive CRC 
patients to define putative new CRC syndromes. Some supportive evidence was also 
found by genetic association and morphological analysis. The rationale for this report was 
to define new syndromes that could be used for future studies of finding new predisposing 
genes. Further studies aiming to find the underlying genetic contribution must be 
undertaken to test these hypothetical syndromes, including replication of the syndrome-
phenotype associations found in our study. 
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10. CONCLUSION AND FUTURE PERSPECTIVES 
 Out of 11 investigated genetic susceptibility loci five showed correlation to specific 
morphologic features. The findings are consistent with pathogenic variants in these 
loci acting in distinct different CRC morphogenic pathways. 
  
 A 5 to 10 year follow-up of our patients could provide prognostic information in 
relation to the investigated SNPs. In case a correlation exists between some or all 
of the loci and prognosis, such information might in the future be used to select 
patients for intensified follow up or treatment. 
 Our data may be useful in understanding the basic tumorigenic pathways linking 
genetic changes and morphology in CRC. Immunostaining for selected markers 
could further elucidate these mechanisms. 
 Since allelic associations may be population specific, our genotype-phenotype 
correlations should be replicated in other populations. 
 
 Tumor location is the factor having most influence on CRC morphology which is in 
line with tumors in different locations having different genetic and embryological 
backgrounds as well as developing in different physiological settings. Age is the most 
important determinant for the presence of multiple tumors and an important factor for 
the aggressiveness of the disease. The results could speak for different mechanisms of 
tumor development in young and old patients. Few morphological features are related 
to sex and only one to family history.  
 
 Emergency CRCs in general show a more aggressive histopathological profile and 
more advanced stage than elective CRC. Our findings could speak for emergency 
CRCs being an inherently different group that may have a different etiological or 
genetic background. 
 
 A 5 to 10 year follow-up of our patients together with an immunohistochemical 
and genetic (SNPs) comparison of the tumors in relation to sex, age, location, 
family history and mode of presentation could indicate which proteins/ molecular 
pathways that differ in the carcinogenesis and if any of these can be used for 
prognostication.  
 In case a correlation is found between prognosis and some of the 
immunohistochemical markers studied, these markers could be included in routine 
pathology making it possible for the pathologist to contribute additional 
prognostic information in the individual case. 
 Even though the surgical aspects are important for the understanding of the worse 
prognosis in emergency CRCs, it is probably also of importance to characterize 
the biology of theses tumors since it might help us to design a more specific 
adjuvant treatment postoperatively. 
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 By using the family history of relatives to CRC patients we have identified five new 
putative CRC syndromes. Some supportive evidence of these was also found by 
genetic association and morphological analysis. 
 
 The concept of new CRC syndromes is intriguing and novel but our findings need 
to be replicated in further studies. 
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